|Numéro de publication||US3797494 A|
|Type de publication||Octroi|
|Date de publication||19 mars 1974|
|Date de dépôt||9 août 1971|
|Date de priorité||1 avr. 1969|
|Numéro de publication||US 3797494 A, US 3797494A, US-A-3797494, US3797494 A, US3797494A|
|Cessionnaire d'origine||Alza Corp|
|Exporter la citation||BiBTeX, EndNote, RefMan|
|Citations de brevets (6), Référencé par (478), Classifications (25)|
|Liens externes: USPTO, Cession USPTO, Espacenet|
United States Patent [191 Zaffaroni ]*Mar. 19, 1974 1 1 BANDAGE FOR THE ADMINISTRATION OF DRUG BY CONTROLLED METERING THROUGH MICROPOROUS MATERIALS  Inventor: Alejandro Zaffaroni,Atherton,
 Assignees Alza Corporation, Palo Alto, Calif.
[ Notice: The portion of the term of this patent subsequent to Aug. 10, 1988, has been disclaimed.
 Filed: Aug. 9, 1971  Appl. No.: 169,976
Related US. Application Data  Continuation-impart of Ser. Nos. 812,116, April 1, 1969, Pat. No. 3,598,122, and Ser. No. 812,117, April 1, 1969, Pat. No. 3,598,123, and Ser. No. 150,085, June 4, 1971, Pat. No. 3,731,683.
 US. Cl. 128/268  Int. Cl A611 15/06  Field of Search l28/260, 268, 156, 155,
 References Cited UNITED STATES PATENTS 3,598,122 8/1971 Zaffaroni 128/268 3,598,123 8/1971 Zaffaroni 128/268 3,426,754 2/1969 Bierenbaum.... 128/268 X 3,053,255 9/1962 Meyer 128/268 3,464,413 9/1969 Goldfarb et 3].. 128/268 3,512,997 5/1970 Cohly et a1. 128/296 X Primary Examiner-Dalton L. Truluck Assistant Examiner-.1. C. McGowan 5 7 ABSTRACT or distributed throughout a reservoir matrix. The drug passes through drug release rate controlling micropo' rous material which continuously meters the flow of drug by viscous or diffusive transfer to the skin or mucosa at a controlled and predetermined rate over a period of time. i
7 Claims, 5 Drawing Figures PATENTEUIAR I 9 1914 INVENTOR.
BY Alejandro Zaffaroni BANDAGE FOR THE ADMINISTRATION OF DRUG BY CONTROLLED METERING THROUGH MICROPOROUS MATERIALS RELATED APPLICATIONS This application is a continuation-in-part of Ser. No. 812,1 l6, filed Apr. 1, 1969, and now issued on Aug. 10, 1971 as US. Pat. No. 3,598,122 entitled Bandage for Administering Drugs"; Ser. No. 812,1 l7, filed Apr. 1, 1969, and now also issued on Aug. 10, 1971 as US. Pat. No. 3,598,123 entitled Bandage; and Ser. No. 150,085, filed June 4, 1971, and now issued on May 8, 1973 as US. Pat. No. 3,731,683 entitled Bandage for the Controlled Metering of Topical Drugs to the Skin; all being applications of Alejandro Zaffaroni.
BRACKGROUND OF THE INVENTION This invention relates to a device for the administration of drug and, more particularly, to a medical bandage for the controlled continuous metering of flow of systemically or topically active drug to the skin or mucosa over a period of time.
Topically active drugs, as that term is used in this specification and the appended claims, are agents which, when applied to the skin or mucosa, primarily cause a pharmacological or physiological response at or near the site of their application. systemically active drugs, as that term is used in this specification and the appended claims, are agents which, when applied to the skin or mucosa, are absorbed through the body surface to which applied and are transported from their site of application by the recipients circulatory system or lymphatic system, to cause a pharmacologic or physiologic response at a remote site in the body.
systemically active drugs are conventionally administered either orally or by injection, with the primary objective of the mode being to achieve a given desired blood level of drug in circulation over a period of time. However, these prior art methods possess certain shortcomings resulting in the failure to obtain these goals. For example, the oral route is inadequate for several reasons even though the drug is administered at periodic intervals according to a well defined schedule. The rate of absorption of drug through the gastrointestinal tract is affected by both the contents of the tract and the time of passage of drug through the small intestine. Therefore, such variables as whether the drug is administered before or after eating and the type and quantity of food eaten (for example, high or low fat content), or whether administered before or after a bowel movement, affect the. rate of absorption of the drug which takes place in the small intestine. Additionally, the time of passage of drug through the small intestine is affected by the rate of peristaltic contracting, adding further uncertainty. Also important is the rate of circulation of blood to the small intestine and the fact that many drugs administered by this route are rendered inactive by gastric acid and digestive enzymes of the gastrointestinal tract or liver where the drug can be metabolized to an inactive product by that organ. These factors make it difficult to achieve a desired time course of concentration of the drug in the blood. The almost inevitable result of oral administration of drugs through the gastrointestinal tract is, that the level of drug in circulation surges to a peak level at the time the drug is administered, followed by a decline in concentration in 2 the blood and body compartments. Thus, a plot of drug in circulation after'administration of several tablets a day has the appearance of a series of peaks which may surpass the toxic threshold of the drug, and valleys which fall below the critical point needed to achieve the desired therapeutic effect.
The administration of drugs by injection can entail certain disadvantages. For example, very strict asepsis must be maintained to avoid infection of the blood, the vascular system or heart. Drug administration by poor intravenous injection technique may result in perivascular injection when it is not intended; and the typical result of injection into the blood is a sudden rise in the blood concentration followed by an uncontrolled decline. Additionally, administration of drugs by injection is inconvenient and painful. Other dosage forms for systemic administration of drug, such as rectal suppositories and sublingual lozenges, also produce non-uniform levels of the therapeutic agent in circulation. These dosage forms require great patient cooperation, have low patient acceptability, and are sparingly used throughout most of the world.
A large number of locally acting drugs are available to treat skin disorders or other conditions which manifest themselves in a manner such that they are susceptible to treatment via the skin. These drugs are conventionally topically administered to the skin with the active agent carried in the form of ointments, creams, salves, liniments, powders, dressings, and the like. The popularity of these types of formulations resides in the fact that it is quite easy to topically apply the agent to the skin in this manner. In most cases, however, it is not possible to determine how much of the preparation has been taken up or effectively administered to the sking since only non-uniform levels of the agent are available, nor is there any assurance that sufficient medication will be available for the duration of periods that it is required. A further undesirable feature is the unsightliness of these formulations which often discourages patients from using them during their waking hours of the day when they are most likely to be seen by others. Further, the preparations are subject to rub off onto clothing, thus causing much inconvenience and annoyance tothe user.
SUMMARY OF THE INVENTION Accordingly, an object of this invention is to provide a bandage for the improved continuous administration of a predetermined controlled quantity of topically or systemically active drug to or through the skin or body mucosa over a period of time, which overcomes the disadvantages inherent in the aforesaid prior art modes of administration.
Another object of this invention is to provide a bandage which can be adapted to deliver controlled quantities of drug having a wide variety of chemical and physical properties and over a wide range of drug delivery rates.
In accomplishing these objects, one feature of the invention resides ina bandage for the continuous administration of controlled quantities of drug to the skin or mucosa, comprised of a laminate of: (l) a backing member; bearing (2) a discrete middle reservoir layer containing a drug confined within a body, the body being formed from drug release rate controlling microporous material permeable to the passage of the drug, to continuously meter the flow of a therapeutically effective amount of the drug to the skin or mucosa from the reservoir at a controlled and predetermined rate over a period of time; and (3) a pressure-sensitive adhesive surface adapted for contact with the skin or mucosa and positioned on one surface of the reservoir remote from the backing member.
Another aspect of this invention resides in a bandage comprised of a laminate of: (l) a backing member; bearing (2) a discrete middle reservoir containing a drug confined therein, the reservoir being formed of material permeable to passage of the drug; and (3) a pressure-sensitive adhesive surface adapted for contact with the skin or mucosa and positioned on one surface of the reservoir remote from the backing member and wherein one or more drug release rate controlling microporous membranes are interposed between the surface of the reservoir and pressure-sensitive adhesive so as to continuously meter the flow of a therapeutically effective amount of the drug from the reservoir at a controlled and predetermined rate over a period of time. The reservoir can be a container having the agent confined therein or a solid or microporous matrix having agent dispersed therein.
Still another embodiment of this invention resides in an adhesive bandage comprising a laminate of: (l) a backing member; bearing (2) a pressure-sensitive adhesive on one surface thereof adapted for contact with the skin or mucosa, said pressure-sensitive adhesive having distributed therethrough, (3) a plurality of discrete microcapsules, each of which microcapsules comprises a drug confined within a body of drug release rate controlling porous material to continuously meter the flow of a therapeutically effective amount of the drug to the skin or mucosa of the patient from the microcapsules at a controlled and predetermined rate over a period of time.
Other objects, features and advantages of the invention will become more apparent from the following description when taken in conjunction with the accompanying drawings.
The term reservoir, as used herein to define the drug containing portion of the subject bandage, is intended to connote a broad class of structures capable of fulfilling'the intended function, and includes both discrete porous microcapsules, as well as distinct reservoir compartments or layers. Likewise, as will be hereinafter more completely developed, the foregoing term encompasses containers having one or more interior drug containing chambers, as well as solid matrices and microporous matrices having a systemically or topically active drug distributed therethrough.
The term drug or agent, when not further qualitied, includes both topically active and systemically active drugs. as hereinbefore defined.
BRIEF DESCRIPTION OF THE DRAWINGS In the drawings:
FIG. 1 is a cross-sectional view of an embodiment of the medical bandage of the invention, wherein the drug is uniformly distributed throughout a matrix of microporous material permeable to the passage of the drug by flow through the pores of the material and the material is laminated to a backing member. The matrix material which acts as a reservoir for the drug bears a coating of the pressure-sensitive adhesive thereon;
FIG. 2 is a cross-sectional view of still another embodiment of the invention, wherein the adhesive bandage of the invention is comprised of a backing member having a reservoir on one surface thereof of drug uniformly distributed throughout a matrix material permeable to passage of the drug, and on the surface of the reservoir remote from the backing member bearing a pressure-sensitive adhesive coating. A microporous membrane is interposed between the reservoir layer and the pressure-sensitive adhesive coating;
FIG. 3 is a cross-sectional view of another embodiment of the bandage of the invention, wherein the reservoir laminated to the backing member is a hollow container permeable to passage of drug by flow through the pores of one surface thereof, and having the drug confined within the interior chamber thereof. The reservoir bears a coating of pressure-sensitive adhesive thereon;
FIG. 4 is a perspective view of the medical adhesive bandage of the invention, wherein the drug is microencapsulated with a porous material permeable to the passage of the drug, and the microcapsules are uniformly distributed throughout the pressure-sensitive coating;
FIG. 5 is a cross-sectional view of the bandage of the invention shown in FIG. 4.
DETAILED DESCRIPTION OF THE INVENTION In accordance with this invention there is provided a bandage suitable, by virtue of the microporous materials employed therein, for the predetermined controlled administration of drug to the skin or mucosa of the body over a period of time. To use the bandage of the invention it is applied to the patients skin or mucosa and should be in firm contact therewith so as to form a tight seal. Flow of drug from the reservoir is metered through the pores of the rate release controlling material in accordance with the laws of hydrodynamics or diffusion, as hereinafter discussed, at a predetermined rate. In operation, drug molecules are continuously removed from the reservoir and migrate to the skin or mucosa of the patient. In the case of systemic drugs, the drugs are absorbed by the skin or mucosa and enter circulation through the capillary network.
The reservoir containing the drug is formed of material permeable to the drug to permit passage of the drug. Depending upon the particular embodiment as described above, the drug reservoir can be of microporous material or otherwise. However, as is apparent in the latter case, the drug must first pass through a microporous membrane material prior to reaching the skin or mucosa. It is therefore critical to the practice of this invention for all embodiments that, at some point after or concurrent with the release of drug from the reservoir and prior to reaching the skin or mucosa, the drug pass through the drug release rate controlling microporous membrane or matrix material to meter the flow thereof. The rate of passage or permeation of drug through the microporous material is determined by the transfer mechanism which can be either by:
l. diffusive flux of drug molecules as is the case, as hereinafter described, where the micropores of the rate controlling microporous membrane or matrix material are impregnated with a diffusive medium for the drug in which the drug molecules can dissolve in and flow through to a direction of lower chemical potential; or
2. pressure induced viscous type flow of drug molecules through the pores in the microporous membrane or matrix rate controlling material.
Thus, the microporous material has a structure that enables the drug to pass through the pre-existing pores or capillaries, either by diffusive permeability or microporous hydrodynamic flow, depending upon the mode of use as describd hereinafter. Since the microporous rate controlling material is preferably selected so that the drug is substantially insoluble therein, as hereinafter described, flow of drug through the structure of the material can be neglected.
For drug transfer mechanism 1) set forth above, i.e., wherein the drug diffuses through a diffusive medium for the drug, the release rate can be controlled in accordance with Ficks First Law, depending on the particular design by selection of dependent variables such as the diffusivity and solubility of the drug in the diffusive medium and the thickness and porosity of the material properly modified by a tortuosity factor. For drug transfer mechanism (2), i.e., flow of drug through the pores of the microporous rate controlling material, the pressure differential, the thickness of the membrane, the viscosity of the permeant drug, the size of the permeant molecule relative to the pore size, the absolute value of the pore size, and the number of pores or percent voids in the material are the controlling factors governing permeability. For the simplest type of flow mechanism of this type, e.g., viscous flow, the amount of drug passing through the porous structure is given by Poiseuilles equation for viscous flow.
Therefore, the selection of appropriate materials for fabricating the microporous rate controlling membrane or matrix material will be dependent on the particular drug to be used in the bandage. Both organic and inorganic polymeric materials can be shaped into a wide variety of forms with tailored morphology and a wide range of chemical and physical properties to advantageously control release of a wide variety of drugs, including those with large molecular structures such as insulin, and over a large dosage range rate appropriate pore size selection. Additionally, by impregnating the interconnected pores of the microporous structure with a diffusive medium for the drug to be administered, a given microporous membrane or matrix material can be adapted to control the release of drugs having a wide range of chemical properties by diffusive permeability. Thus, by varying the composition, pore size, and effective thickness of the microporous rate controlling material, the viscosity of the drug to be administered by appropriate formulation or by impregnating the material with suitable solvent, the dosage rate per area of bandage can be controlled since the material functions to meter the flow of drug from the device. Therefore, bandages of the same surface area can provide different dosages of a drug by varying the above discussed parameters.
The microporous rate controlling materials of this invention are known in the art and can be visualized as a plurality of sponge-like fused polymer particles which provide a supporting structure having therethrough a dispersion of microscopic sized interconnecting voids or pores. The rate controlling structures formed from the materials can be isotropic, wherein the structure is homogeneous throughout the cross-section of the matrix or membrane material, or anisotropic wherein the structure is non-homogenous. These rate controlling structures are commercially available and can be made by a multitude of different methods, e.g., etched nuclear track, and materials employed, e.g., polyelectrolyte, ion exchange polymers, as described in R. E. Kesting, Synthetic Polymer Membranes, McGraw Hill, Chapters 4 and 5, 1971; J. D. Ferry, Ultrafiltration Membranes, Chemical Review, Vol. 18, Page 373, 1934. Materials possessing from 5 percent to 95 percent voids and having an effective pore size of from about 10 angstroms to about 100 microns can be suitably employed in the practice of this invention. Materials with pore sizes significantly below angstroms can be considered to be molecular diffusion type membranes and matrices. In order to obtain the most advantageous results, the materials should be formed into structures with the desired morphology in accordance with methods known to those skilled in the art to achieve the desired release rate of drug. Additionally, the material must have the appropriate chemical resistance to the drug used and be non-toxic when used as an element of the bandage of the invention.
Materials useful in forming the microporous rate controlling materials used in this invention include, but are not limited to the following.
Polycarbonates, i.e., linear polyesters of carbonic acids in which carbonate groups recur in the polymer chain, by phosgenation of a dihydroxy aromatic such as bisphenol A. Such materials are sold under the trade designation Lexan'by the General Electric Company.
Polyvinylchlorides; one such material is sold under the trade designation Geon 121 by B. G. Goodrich Chemical Company.
Polyamides such as polyhexamethylene adipamide and other such polyamides popularly known as nylon. One particularly advantageous material is that sold under the trade name NOMEX by E. I. DuPont de Nemours & Co.
Modacrylic copolymers, such as that sold under the trade designation DYNEL and formed of polyvinylchloride percent) and acrylonitrile (40 percent), styrene-acrylic acid copolymers, and the like.
Polysulfones such as those of the type characterized by diphenylene sulfone groups :in the linear chain thereof are useful. Such materials are available from Union Carbide Corporation under the trade designation P-l700.
Halogenated polymers such as polyvinylidene fluoride sold under the trade designation Kynar by Pennsalt Chemical Corporation, polyvinylfluoride sold under the trade name Tedlar by E. I. DuPont de Nemours & Co. and the polyfluorohalocarbon sold under the trade name Aclar by Allied Chemical Corporation.
Polychloroethers such as that sold under the trade name Penton by Hercules Incorporated, and other such thermoplastic polyethers.
Acetal polymers such as the polyformaldehyde sold under the trade nambe Delrin by I. DuPont de Nemours & Co., and the like.
Acrylic resins such as polyacrylonitrile polymethyl poly (vinyl alcohol); polyelectrolyte structures formed of two ionically associated polymers of the type as set forth in U.S. Pat. Nos. 3,549,016 and 3,546,142; derivatives of polystyrene such as poly (sodium styrenesulfonate) and polyvinylbenzyltrimethyl-ammonium chloride); poly( hydroxyethyl methacrylate poly(isobutyl vinyl ether), and the like, may also be utilized. A large number of copolymers which can be formed by reacting various proportions of monomers from the aforesaid list of polymers are also useful for preparing rate controlling structures useful in the invention.
As illustrated in FIG. 1, the bandage of the invention is comprised of drug 24 uniformly distributed in the interstices of the microporous matrix material forming reservoir 22. The matrix material is laminated to backing member 21 and bears a pressure-sensitive adhesive coating 23 thereon. The microporous matrix material 22 functions to control the release rate of the drug impregnated therein. The reservoir can be prepared by employing any of the known impregnating techniques. Thus, the drug can be added to the rate controlling material in liquid form and uniformly distributed therethrough by mixing, and subsequently converted to a microporous structure by the various methods known to the art. One such method calls for dissolving a natural or synthetic polymer in a suitable solvent in which it has sufficient solubility to permit the preparation of a solution that is sufficiently viscous for conventional film casting. The preferred method is to cast a film of a polymer solution having the drug therein, and, shortly after casting, to immerse it in a non-solvent or diluent, a medium which is compatible with the solvent, but not a solvent for the polymer. The original solution then forms two phases, one polymer-rich and one polymer-poor. Under the proper conditions, both of these phases are physically continuous, so that the resulting polymer membrane is mechanically reasonably strong, but it is completely interlaced with continuous pores. The size and uniformity of the pores depend on the conditions of preparation. Alternatively, preformed microporous materials can be impregnated with drug by immersion in a bath of the drug to diffuse the drug into the material. While the matrix material can be of any convenient thickness, typically a thickness of from 20 to 200 microns is employed.
FIG. 2 illustrates a further modified form of the invention wherein the adhesive bandage 30 of the invention is comprised of a backing member 21 having a reservoir 32 on one surface thereof. A microporous rate controlling membrane 35 is interposed between the reservoir 32 and a pressure-sensitive adhesive coating 23. Drug 24 is confined in polymeric matrix material 32 which acts as the reservoir for the drug. Matrix material 32 can be solid material as illustrated, or microporous as illustrated for reservoir 22 in FIG. 1. If desired, additional membranes can be juxtaposed next to membrane 35 in order to achieve optimum rate release properties. The matrix material 32 when solid or microporous should have a release rate to drug which is higher than that of the rate controlling microporous membrane 35, such that passage through the latter is the rate controlling step. Materials used to form the matrix reservoir 32 of FIG. 2, when solid, can be those heretofore exemplitied for preparing the microporous rate controlling material and, in addition, include hydrophobic polymers such as plasticized or unplasticized polyvinylchloride, plasticized nylon, plasticized soft nylon, plasticized polyethyleneterephthalate, natural rubber, C -C olefins, e.g., polyethylene, polyisoprene, polyisobutylene, polybutadiene; silicone rubbers, especially the medical grade polydimethylsiloxanes, as described in US. Pat. No. 3,279,996, hydrophilic polymers such as the hydrophilic hydrogels of esters of acrylic and methacrylic acid (as described in US. Pat. Nos. 2,967,576 and 3,220,960, and Belgian Patent No. 701,813), modified collagen, cross-linked polyvinylalcohol, and crosslinked partially hydrolyzed polyvinylacetate. Of course, these materials used to form the matrix must be permeable to passage of the drug, as by diffusion. Accordingly, selection of appropriate materials will, in each instance, be dependent on the particular drug to be administered.
FIG. 3 illustrates a further form of the invention wherein bandage 40 includes a backing member 21 and a reservoir 42 in the form of a hollow container having an interior chamber 43 containing drug 34. Wall or surface 45 of reservoir 42, remote from backing member 21, is of a microporous membrane structure permeable to passage of drug 34, to meter the flow of drug to pressure-sensitive adhesive layer 23 on the outer surface thereof. The sides of the reservoir 42, other than rate controlling microporous membrane 45, preferably are impermeable to passage of the drug, and can be made of the same materials used to make the backing member as hereinafter described. As discussed, one face surface of the drug reservoir bears a backing member 21. The purpose of the backing is to prevent passage of the drug through the surface of the reservoir distant from the adhesive layer. An ancillary purpose of the backing is to provide support for the bandage where needed. When the outer surface of the reservoir 33 is impermeable to the drug and strong enough, the backing becomes unnecessary. The other surface of the reservoir bears a coating of a pressure-sensitive adhesive.
If desired, additional microporous rate controlling membranes can be juxtaposed on top of membrane 45 to further tailor the rate of flow of drug. Of course, in each instance, the membrane will have different characteristics than the reservoir membrane 45 of the particulardevice. This use of a pair of multiplicity of membranes, that is, the reservoir wall and the further membrane, allows for precise metering of drug out of the reservoir; for the thickness, porosity and composition of both membranes can be varied to provide for wide range of dosage levels for a given area of bandage. It will be appreciated that this type of membrane can be used with either the matrix (FIGS. 1 or 2) or container type (FIG. 3) of reservoir. To provide additional mechanical strength, if necessary, the rate controlling microporous membrane 45 can be supported by an appropriate mesh or screen having a greater release rate to drug than does membrane 45. v
The reservoir of the embodiment in FIG. 3 can be formed by molding into the form of a hollow container with the drug trapped therein. While the non-rate controlling walls of the reservoir can be of any convenient thickness, usually they have a thickness of from 0.01 to 7 millimeters. The rate controlling membranes 35 and 45, in FIGS. 2 and 3, respectively, can have varying thickness depending upon the nature of the membrane, its porosity and the number of membranes used in combination. Typically, a thickness of from 20 to 200 microns is employed.
It will, of course, be appreciated that the pressuresensitive adhesive surface need not form a continuous layer on the subject bandage. Particularly in the case of a bandage having a distinct reservoir layer, equally advantageous results are obtained by providing an annu lar surface of adhesive around the periphery of the bandage face. In this manner a liquid tight adhesive seal between the bandage and the patients skin or mucosa is maintained, and at the same time, drug may be directly absorbed by the skin from the exposed surface of the drug reservoir layer without first migrating through an adhesive layer. As a further alternative, in the embodiment of the invention employing a distinct reservoir layer, to prevent passage of the drug into the adhesive layer prior to use, the adhesive can be supplied separately from the reservoir and backing, with the device assembled at the point of use. For example, the adhesive in sheet form can have both surfaces protected with a release film and the wall of the reservoir can be similarly protected. At the point of use, the release films can be removed from the reservoir and one surface of the adhesive, the adhesive sheet applied to the reservoir wall to complete assemblage of the bandage, the remaining release film then removed from the adhesive, and the bandage then applied to the patient.
As previouslydiscussed, one type of drug transfer mechanism is that of flow through the pores or pinholes in microporous rate controlling material. A driving force, Le, a pressure differential across the microporous material, is necessary to cause the flow of drug by this mode. The bandage of the type illustrated in FIG. 3, wherein the reservoir is a hollow container, can be conveniently adapted to meter the flow of drug by a microporous hydrodynamic mechanism by pressurizing the container. This can suitably be accomplished by admixing with the drug a solid particulate material which liberates gas on contact with the drug formulation. For example, in the case wherein the formulation is of an aqueous nature, a conventional effervescent powder such as a mixture of citric acid and sodium bicarbonate can be inserted immediately prior to use through an opening in the reservoir wall so provide for this purpose. After insertion of the effervescent material, the opening is sealed, for example, by means of an adhesive tape. The pressure can be controlled by adjusting the particle size of the effervescent powder composition and the quantity thereof. Pressure in an amount of from 1 mm to 50 mm of mercury can be satisfactorily employed, with the actual amount depending upon the desired release rate and the other parameters previously discussed regarding viscousflow.
FIGS. 4 and 5 illustrate an adhesive bandage of the invention including a backing member 11 bearing a pressure-sensitive adhesive coating 12 on one surface thereof. Adhesive coating 12 has uniformly distributed therethrough microcapsules 13 comprising drug encapsulated with a microporous rate controlling material permeable to passage of the drug. Thus, in the embodiment illustrated herein, porous microcapsules 13 constitute the drug reservoir.
To provide the microcapsules, the encapsulating material can be uniformly impregnated with the drug to form microcapsules which are a porous matrix having the drug distributed therethrough. Alternatively, particles of drug can be encapsulated with a thin microporous-coatingof the encapsulating material to form microcapsules having an interior chamber containing the drug. If desired, particles of a matrix, such as starch, gum acacia, gum tragacanth, and polyvinylchloride, can be impregnated with the drug and encapsulated with other materials such as the microporous rate controlling materials previously described, which function to meter the flow of drug to the adhesives; use of a microporous matrix and a different rate controlling membrane coating to slow the passage of the drug from the microcapsules, which is desirable: with drugs that are released too rapidly from available encapsulating materials, is therefore also contemplated herein.
Any of the encapsulation or impregnation techniques known in the art can be used to prepare the microcapsules to be incorporated into the pressure-sensitive adhesive in accord with the embodiment of FIGS. 4 and 5. The porous microcapsules can be made by techniques as set forth in US. Ser. No. 751,251, corresponding to German Patent No. 1,939,066, entitled Microcapsules with Anisotropic MicroporousLiquid Permeable Polymeric Outer Skin and Internal Macroporous Support Partitions or Structure, Bixler, Michaels, and Sternberg, or by standard coacervation methods. The coacervation method of fabrication, as conventionally employed, consists essentially of the formation of three immiscible phases, a liquid manufacturing phase, a core material phase and a coating phase with deposition of the liquid polymer coating on the core material and rigidizing the coating, usually by thermal, cross-linking or desolvation techniques to form microcapsules. Usually, the microcapsules made by the above techniques have an average particle size of from several tenths of a micron to 5,000 microns, although this feature is not critical to the practice of the invention. Techniques for preparing microcapsules, such as the classic Bungenberg de long and Kass method are reported in Biochem. Z, Vol. 232, Pg. 338 to 345, I931; Colloid Science, Vol. 11, Reversible System,edited by H. R. Kruyt, 1949, Elsevier Publishing Company, Inc., New York; J. Pharm. Sci, Vol. 59, No. 10, Pg 1367 to 1376, 1970; and, Remingtons Pharmaceittical Science, Vol. XIV, Pg. 1676 to 1677, 1970, Mack Publishing Company, Easton, Pennsylvania. Thus, the drug can beadded to the encapsulating material in liquid form and uniformly distributed therethrough by mixing and then forming the microcapsules by any of the above set forth methods. Alternatively, the porous microparticles can be made by the above techniques and impregnated with drug. Still another method is to impregnate a porous solid encapsulating material with a drug by immersion in a bath of the drug to diffuse the drug-into the material, and subsequently the solid material can be, reduced to fine microcapsules by grinding, each of the microcapsules comprising drug coated with and distributed throughout the encapsulating material. Further, drug can be encapsulated with a microporouscoating by suspending dry particles of the drug in an air stream and contacting that stream with a stream containing the encapsulating material to coat the drug particles. Usually, the micro-capsules have an average particle size of form 1 to 1000 microns, although this is not critical to the invention. The microcapsules, however made, are then mixed by conventional methods, e.g., stirring, ballmilling, and the like, with a pressure-sensitive adhesive. The mixture of microcapsules and pressure-sensitive adhesive is then coated onto a backing member, usually to provide an adhesive layer 0.01 to 7 millimeters thick, although these limits can be exceeded if more or less drug is required. The purpose of the backing is to provide support for the bandage and to prevent passage of the drug through the adhesive surface away from the body surface to which the bandage is applied.
As above discussed, the microporous rate controlling materials can be adapted to control the release of drug 1 by diffusive permeation wherein the micropores are impregnated or otherwise filled with a diffusive medium for the drug to be administered. The material can be impregnated with the diffusive medium by methods well known to the art, e.g., as by immersion in a bath of the material to permit the diffusive medium material to fully saturate the micropores. The impregnation technique can be employed with any of the embodiments represented herein. In embodiments illustrated in FIGS, 1, 4 and 5 the micropores can be concurrently impregnated with both drug and diffusive medium material.
In cases where the pressure-sensitive adhesive and microporous rate controlling material employed are water permeable, body fluids will self-migrate into the microporous material after the bandage has been in contact with the skin for a suitable period of time to provide the diffusive medium, as hereinafter described, without the necessity of carrying out a separate impregnation step. Additionally, the pores can be self-filled by migration of the diffusive medium by contact with the composition employed to prepare the drug formulation, as later described.
The diffusive medium is one which enables the drug to dissolve therein and flow by diffusion at the desired rate. It can be either of a liquid or solid nature and be a poor or good solvent for the drug. A medium with poor solvent properties for the drug is desired when the required release rate is low and of course the converse is true when the desired release rate is high.
The art provides many useful approaches to enable selection of particular solvent-drug systems. Specific attention is called to Remingtons Pharmaceutical Sciences, Chapters 19 and 71. The solvent selected must be non-toxic and one in which the rate controlling microporous material has the required solubility. The materials which are useful for impregnating the micropores can be polar, semi-polar or non-polar. Exemplary are any of the pharmaceutically acceptable solvents such as water, alcohols containing 2 to carbon atoms, such as hexanol, cyclohexanol, benzylalcohol, 1,2-butanediol, glycerol, and amyl alcohol; hydrocarbons having 5 to 12 carbon atoms such as n-hexane, cyclohexane, and ethyl benzene; aldehydes and ketones having 4 to 10 carbon atoms such as heptyl aldehyde, cyclohexanone, and benzaldehyde; esters having 4 to 10 carbon atoms such as amyl acetate and benzyl propionate; etheral oils such as oil of eucalyptus, oil of rue, cumin oil, limonene, thyme], and l-pinene; halogenated hydrocarbons having 2 to 8 carbon atoms such as n-hexyl chloride, n-hexyl bromide, and cyclohexyl chloride; or mixtures of any of the foregoing materials.
Also suitable are many of the conventional non-toxic plasticizers used in the fabrication of microporous rate controlling material, e.g., octyl diphenyl phosphate. When these plasticizers are suitable diffusive materials for the drug used, advantageously, the necessity for filling the pores by a separate step is thus obviated. Other plasticizers known to the art can be employed, such as long-chain fatty amides, higher alcohols, and high boiling esters such as di(isooctyl) sebacate or di(2-ethyl hexyl) phthalate.
It is preferred that the diffusive medium also be incorporated in the reservoir in combination with the drug in the form of a pharmaceutically acceptable carrier as hereinafter described.
In practicing this invention one can employ any systemically active drug which will be absorbed by the body surface to which the bandage is applied, consistent with their known dosages and uses. Of course, the amount of drug necessary to obtain the desired therapeutic effect will vary depending on the particular drug used. Suitable systemic drugs include, without limitation, Anti-microbial Agents such as penicillin, tetracycline, oxytetracycline, chlortetracycline, chloramphenicol, and sulfonamides; Sedatives and Hypnotics such as pentabarbital sodium, phenobarbital, secobarbital sodium, codeine, (oz-bromoisovaleryl) urea, carbromal, and sodium pheno-barbital; Psychic Energizers such as 3-( Z-aminopropyl) indole acetate and 3-( 2- aminobutyl) indole acetate; Tranquilizers such as reserpine, chlorpromazine hydrochloride, and thiopropazate hydrochloride; Hormones such as adrenocorticosteroids, for example, 6a-methylprednisolone; androgenic steroids, for example, methyltestosterone, and fluoxymesterone; estrogenic steroids, for example, estrone, l7B-estradiol and ethinyl estradiol; progestational steroids, for example, l7a-hydroxyprogesterone acetate, medroxyprogesterone acetate, 19-norprogesterone, and norethindrone; and thyroxine; Antipyretics such as aspirin, salicylamide, and sodium salicylate; morphine and other narcotic analgesics; Antidiabetics, e.g., insulin; Cardiovascular Agents, e.g., nitroglycerin, and cardiac glycosides such as digitoxin, digoxin, ouabain; Anti-spasmodics such as atropine, methscopolamine bromide, methscopolamine bromide with phenobarbital; Anti-malarials such as the 4-aminoquinolines, 9-amino-quinolines, and pyrimethamine; and Nutritional Agents such as vitamins, essential amino acids, and essential fats.
Additionally, in practicing this invention one can employ a wide variety of topically active drugs consistent with their known dosages and uses. Suitable drugs include, without limitation: Antiperspirants, e.g., aluminum chloride; Deodorants, e.g., hexachlorophene, methylbenzethonium chloride; Astringents, e. g., tannic acid; Irritants, e.g., methyl salicylate, camphor, cantharidin', Keratolytics, e.g., benzoic acid, salicylic acid, resorcinol, iodochlorhydroxyquin; Antifungal Agents, such as tolnaftate, griseofulvin, nystatin and amphotericin; Anti-inflammatory Agents, such as corticosteroids, e.g., hydrocortisone, hydrocortisone-acetate, prednisolone, methylprednisolone, triamcinolone acetonide, fludrocortisone, flurandrenolone, flumethasone, dexamethasone sodium phosphate, bethamethasone valerate, fluocinolone acetonide; fluorometholone; and pram'ox'ine fiCl; Anti-neoplastic Agentsiegl, methotrexate; and Antibacterial Agents, such as bacitracin, neomycin erythromycifi,tetfacycline HCl, chlortetracycline I-lCl, chloramphenicol, oxytetracycline, polymyxin B, nitrofuraxone, mafenide (a-amino-ptoluenesulfonamide), hexachlorophene, benzalkonium chloride, cetalkonium chloride, methylbenzethonium chloride, and neomycin sulfate.
It will be appreciated, with regard to the aforesaid list of drugs, that characterization of the drug as either systemically or topically active is done for purposes of convenience only. Further, a given drug can be both systemically and topically active depending upon its manner of use.
In addition to the aforementioned drugs, simple pharmacologically acceptable derivatives of the drugs, such as ethers, esters, amides, acetals, salts, etc., or formulations of these drugs, having the desired polymeric permeability or transport properties can be prepared and used in practicing the invention. Drugs mentioned above can be used alone or in combination with others and each other. Of course, the derivatives should be such as to convert to the active drugs within the body through the action of body enzyme assisted transformations, pH, etc.
The above drugs and other drugs can be present in the reservoir alone or in combination form with pharmaceutical carriers. The pharmaceutical carriers acceptable for the purpose of this invention are the art known carriers that do not adversely affect the drug, the host, or the material comprising the drug delivery device. Suitable pharmaceutical carriers include sterile water; saline, dextrose; dextrose in water or saline; condensation products of castor oil and ethylene oxide combining about 30 to about 35 moles of ethylene oxide per mole of castor oil; liquid glyceryl triester of a lower molecular weight fatty acid; lower alkanols; oils such as corn oil; peanut oil, sesame oil and the like, with emulsifiers such as mono-or di-glyceride of a fatty acid, or a phosphatide, e.g., lecithin, and the like; glycols; polyalkylene glycols; aqueous media in the presence of a suspending agent, for example, sodium carboxymethylcellulose; sodium alginate; poly(vinylpyrrolidone); and the like, alone, or with suitable dispensing agents such as lecithin; polyoxyethylene stearate; and the like. The carrier may also contain adjuvants such as preserving, stabilizing, wetting, emulsifying agents, and the like.
The drug can also be mixed in the reservoir with a transporting agent, that is, a material that aids or assists the drug delivery device to achieve the administration of a drug to a drug receptor, for example, by enhancing penetration through the skin. The transporting aids suitable for the purpose of the invention are thetherapeutically acceptable transporting aids that do not adversely affect the host, the drug, or alter or adversely affect the materials forming the drug delivery device. The transporting aids can be used alone or they can be admixed with acceptable carriers and the like. Exemplary of transporting aids include manovalent, saturated and unsaturated aliphatic cycloaliphatic and aromatic alcohols having 4 to 12 carbon atoms, such as hexanol, cyclohexane and the like; aliphatic cycloaliphatic and aromatic hydrocarbons having from 5 to 12 carbon atoms such as hexane, cyclohexane, isopropylbenzene and the like; cycloaliphatic and aromaticaldehydes and ketones having from 4 to carbon atoms such as cyclohexanone; acetamide; N,N-di(lower) alkyl acetamides such as N,N-diethyl acetamide, N,N- dimethyl acetamide, N-( Z-hydroxyethyl) acetamide, and the like; and other transporting agents such as aliphatic, cycloaliphatic and aromatic esters; N,N-dilower alkyl sulfoxides; essential oils; halogenated or nitrated aliphatic, cycloaliphatic and aromatic hydrocar- T4 bons; salicylates; polyalkylene glycol silicates; mixtures thereof; and the like.
The amount of active agent to be incorporated in the bandage to obtain the desired therapeutic effect will vary depending upon the desired dosage, the permeability of the rate controlling materials of the bandage which are employed to the particular agent to be used, and the length of time the bandage is to remain on the skin or body mucosa. Since the bandage of this invention is designed to control drug administration for an extended period of time, such as 1 day or more, there isno critical upper limit on the amount of agent incorporated into the bandage. The lower limit is determined by the fact that sufficient amounts of the agent must remain in the bandage to maintain the desired dosage. In order to achieve a therapeutic effect in a human adult, the daily release dosage of atropine should be in the range of between 200 and 600 micrograms per day. Thus, for example, using atropine and with a bandage intended to remain in place for 1 week, and with a release rate of 500 micrograms of atropine per day, at least 3.5 mg of atropine would be incorporated in the bandage. Generally, the drug delivery bandages made according to the invention can release at a controlled rate about 25 nanograms to about 1 gram of drug or larger amounts per day. Of course, other devices for use for different time periods such as Week or month are also readily made by the invention.
The effective rate of release of the active agent to the skin or mucosa can be in the range of from 0.5 to 1000 micrograms per square centimeter of bandage per day. The exactamount will depend on the desired dosage as well as the condition to be treated. The desired effective rate of release of active agent can be obtained by altering the earlier discussed parameters affecting the release ratecontrolling barrier. In the case of the micro-encapsulated active agent, the release rate can also be controlled by varying the number of microcapsules present in a given volume of the matrix of the device. This is a particularly desirable feature of this aspect of the invention. Additionally, the duration of action of the device can be altered by controlling the amount of active agent initially incorporated consistent with the release rate. Further, the release rate of drug, as well as the duration of release of the drug from the device, can be predetermined to be in consonance with the optimum therapeutic values. Once thisdosage level in micrograms per square centimeter of bandage has been determined, the total amountof drug to be incorporated in the bandage can be established by obtaining the release rate of the agent in the particular material or materials which are to be used; Those skilled in the art can readily determine the rate of permeation of agent through the porous rate controlling material or selected combinations of rate controlling materials. Standard techniques are described in Encyl. Polymer Science and Technology, Vo. Sand 9, Pg. 65 to and 795 to 807, 1968; and the references cited therein.
Any of the well-known dermatologically acceptable pressure-sensitive adhesives can be used in practicing this invention. Exemplary adhesives include acrylic or methacrylic resins such as polymers of esters of acrylic or methacrylic acid with alcohols such as n-butanol, npentanol, isopentanol, 2-methyl butanol, l-methyl butanol, l-methyl pentanol, Z-methyl pentanol, 3-methyl pentanol, 2-ethyl .butanol, isooctanol, n-decanol, or ndodecanol, alone or copolymerized with ethylenically unsaturated monomers such as acrylic acid, methacrylic acid, acrylamide, methacrylamide, N-
alkoxymethyl acrylamides, N-alkoxymethyl methacrylamides, N-tert. butylacrylamide, itaconic acid, vinylacetate, N-branched alkyl maleamic acids wherein the alkyl group has to 24 carbon atoms, glycol diacrylates, or mixtures of these; natural or synthetic rubbers such as silicone rubber, styrenebutadiene, butylether, neoprene, polyisobutylene, polybutadiene, and polyisoprene; polyurethane elastomers; vinyl polymers, such as polyvinylalcohol, polyvinyl ethers, polyvinyl pyrrolidone, and polyvinylacetate; ureaformaldehyde resins; phenolformaldehyde resins; resorcinol formaldehyde resins, cellulose derivatives such as ethyl cellulose, methyl cellulose, nitrocellulose, cellulose acetatebutyrate, and carboxymethyl cellulose; and natural gums such as guar, acacia, pectins, starch, dextrin, albumin, gelatin, casein, etc. The adhesives may be compounded with tackifiers and stabilizers as is well know in the art.
When the adhesive layer covers one face surface of the bandage or when the reservoir is in the form of microcapsules distributed throughout the adhesive, the adhesive must be permeable to passage of the drug to allow drug released from the reservoir to reach the outer surface of the bandage in contact with the patient. In such cases, the rate of release of drug from the adhesive should exceed the rate of release of drug from the reservoir so that release from the reservoir by passage through the drug release controlling microporous material is the rate limiting step for drug administration by the device of the invention. Of course, when the adhesive is disposed only about the periphery of the bandage face, the adhesive need not be permeable to passage of the drug.
Various occlusive and non-occlusive, flexible or nonflexible backing members can be used in the adhesive bandage of the invention. Suitable backings include cellophane, cellulose acetate, ethylcellulose, plasticized vinylacetate-vinylchloride copolymers, polyethylene terephthalate, nylon, polyethylene, polypropylene, polyvinylidenechloride, paper, cloth, and aluminum foil. Preferably, a' flexible occlusive backing is employed to conform to the shape of the body member to which the adhesive tape is applied and to enhance administration of the agent to the skin.
To prevent passage of the drug away from the exposed surface of the pressure-sensitive adhesive prior to use, the adhesive surface of the tape generally is covered with a protective release film or foil such as waxed paper. Alternatively, the exposed rear surface of the backing member can be coated with a low-adhesion backsize and the bandage rolled about itself. To enhance stability of the active compounds, the therapeutic bandage usually is packaged between hermetically sealed polyethylene terephthalate films under an inert atmosphere, such as gaseous nitrogen.
To use the adhesive bandage of the invention, wherein the drug is topical, it is applied directly to the area of skin to be treated, to release a therapeutically effective amount of the agent to the affected area. For administration of systemic drugs the bandage can be applied to any area of the patients skin, with the lower back and buttocks being the areas of choice. In like manner, the bandage can be applied to the mucosa of the mouth, for example, by application to the palate or the buccal mucosa, to obtain absorption of the drug by the oral mucosa. Although obtaining a liquid tight adhesive seal between the skin and bandage is important, it becomes critical in the mouth. Without such a seal, irrigation of the oral mucosa by saliva will transfer the drug to the gastrointestinal tract, rather than to circulation through the oral mucosa. In addition, the bandage of the invention can be used to administer drugs to other mucosa of the body, for example, it can be applied to the vaginal mucosa, rectal mucosa, etc. By use of this invention, one ensures that an accurately measured quantity of the active drug is available to the site of application.
The following examples are merely illustrative to the present invention and should not be construed as limiting the scope of the invention in any way, as these examples and other equivalents thereof will become apparent to those versed in the art in light of the present disclosure, drawings and accompanying claims.
EXAMPLE 1 Porous, discrete particles of polymerized poly(vinyl chloride) of about 100 microns in diameter are prepared by mixing 100 grams of suspension grade poly(- vinyl chloride) resin with 50 grams of octyl diphenyl phosphate and 10 grams of nitroglycerin. These ingredients are mixed at room temperature into a sticky, wet mass. Next, the solvent is allowed to escape to form dry, free flowing, discrete micro-capsules. 10 grams of the resulting microcapsules of polyvinylchloride/nitroglycerin are mixed with 100 grams of a 22 percent solution in hexane: isopropyl-acetate (:30) of a viscoelastic copolymer of isooctyl acrylate and acrylic acid (94:6) adhesive to uniformly distribute the microcapsules throughout the adhesive solution. The resulting slurry is coated onto a cellophane sheet 10 centimeters in width by centimeters in length and the solvent removed from the coated film.
When a 5 centimeter by 5 centimeter section is cut from the above sheet and applied to the skin of a human adult, the resulting bandage is effective to control the continuous administration of a daily therapeutically effective dosage of nitroglycerin for the prophylactic treatment of angina pectoris.
EXAMPLE 2 Dry crystalline powdered megesterol acetate (0.3 gram) in 10 ml. ethanol is mixed with 25 parts by weight of polydimethylsiloxane, 5 parts by weight of silicone oil and 0.25 parts by weight of stannous octoate catalyst. The ingredients are mixed until a homogenous mixture is produced. The mixture is then cast into a mold and allowed to cure to prepare a matrix having a surface area of 10 square centimeters and 9 mils thick. One face surface of the matrix is bonded to a sheet of cellophane. On the other face surface is placed an ethanol impregnated microporous membrane of the same external surface area as the matrix. The membrane is sold by Millipore Corporation and designated to the trade as HA, and is characterized by a porosity of 60 percent, a pore size of 0.45 microns, and a thickness of 4 mils. Dimethyl silicone rubber adhesive is coated to a thickness of 2 mils on the membrane. The adhesive face surface of the completed bandage has an area of 10 square centimeters. The bandage is effective to slowly release megesterol acetate, and when applied to the female skin, is useful for fertility control.
EXAMPLE 3 10 milligrams of betamethasone in 10 ml. of propylene glycol is placed on a sheet of dimethyl silicone rubber having a thickness of 10 mils. The sheet is folded to provide a surface area of l square centimeters on each face and the flaps sealed with silicone adhesive to provide a thin envelope containing the drug. The top face of the envelope is removed and replaced with a propylene glycol impregnated microporous membrane sold by Amicon Corporation under the designation of PM 30. The membrane is secured to the envelope by means of adhesive to form a tight seal therewith. The membrane is characterized by having an anisotropic structure, with a minimum pore size of 70 angstrom units, an overall porosity of 70 percent, and a thickness of 4 units.
Pressure-sensitive adhesive is prepared by mixing together 90 grams of polyacrylate solution (ethylacetate: hexane/:1) containing 25 percent non-volatile matter (obtained by the catalytic polymerization of isomylacrylate and acrylic acid in the ratio of 95:5 in ethylacetate and then diluting with hexane), 5 grams polyvinylethylether (reduced viscosity= 0.3 i 0.1), 1 gram Castor oil (fislfiand l gra r n s pblyethyleneglycol 400.
One face surface of the envelope is bonded to a sheet of cellophane while the external membrane surface is coated with adhesive prepared above to a thickness of 2 millimeters. The adhesive face surface of the bandage has an area of 100 square centimeters. The bandage is effective to release a therapeutically effective daily dosage of the drug when applied to the skin for control of psoriasis.
EXAMPLE 4 3 grams of a polyacrylonitrile fiber sold under the trade designation Orlon by E. I. DuPont de Nemours & Co. was dissolved in 30 grams of an aqueous solution comprising 70 percent by weight of zinc chloride. After the solution was cooled to about 25C, 0.250 grams of DIGOXIN was added to the solution. Thereupon, the solution was added drop-wise through a No. 21 hypodermic needle into an acetone bath whereupon particles were formed. After being stirred for about thirty minutes in the acetone, the particles were removed and placed in a water bath for four hours at room temperature to leach our residual acetone and salt.
grams of polyvinylethylether (reduced visosity= 5 .0 i 0.5) 4 grams of polyvinylethylether (reduced viscosity= 4 grams of glycerol ester of hydrogenated rosin and 2 grams polyethyleneglycol 400 The resulting DIGOXIN capsules are mixed with pressuresensitive adhesive prepared above to uniformly distribute the microcapsules throughout the adhesive. Immediately thereafter, the adhesive mixture is coated onto one surface of a 1000 square centimeter Mylar sheet. A 5 centimeter by 5 centimeter area of the resulting bandage can be used for control of cardiac disorders.
Thus, this invention provides an easy to use device for administering systemically active drugs through the skin or oral mucosa and other body mucosa. Uncertainties of administration through the gastrointestinal tract are avoided and a controlled constant level of drug in circulation can be obtained. Treatment is begun by applying the bandage to the skin or mucosa and terminated by removing it therefrom. The bandage can contain and administer the complete dosage requirements for a particular time period, for example, 24 hours. Intervention by the patient is required only to apply and remove the bandage, so that uncertainties through patient error are eliminated.
Moreoventhis invention provides a reliable and easy to use device for administering topically active drugs directly to the affected areas of skin or mucosa. Uncertainties resulting from topical application of these agents, from creams and solutions, are not encountered; and a precisely determined amount of the drug is applied in a controlled manner.
Although the product of this invention has been referred to as an adhesive bandage, those skilled in the art will appreciate that the term adhesive bandage" as used herein includes any product having a backing member and a pressure-sensitive adhesive face surface. Such products can be provided in various sizes and configurations, including tapes, bandages, sheets, plasters, and the like.
What is claimed is:
l. A medical bandage for the continuous administration of controlled quantities of drug to the skin or mucosa, comprised of a laminate of: (l) a backing mem' ber; bearing (2) a discrete middle reservoir layer containing a drug confined within a body, the body being comprised of drug release rate controlling microporous material permeable to the passage of drug, to continuously meter the flow of a therapeutically effective amount of the drug to the skin or mucosa from the reservoir at a controlled and predetermined rate over a period of time; and (3) a pressure-sensitive adhesive surface adapted for contact with the skin or mucosa and postitioned on one surface of the reservoir remote from the backing member.
2. The bandage as defined by claim 1 wherein the pores of the microporous rate controlling material are filled with a medium to permit controlled diffusion of the drug from the reservoir.
3. A medical bandage for the continuous administration of controlled quantities of drug to the skin or mucosa, comprised of a laminate of: (l) a backing member; bearing (2) a discrete middle reservoir containing a drug confined therein, the reservoir being formed of material permeable to passage of the drug; and (3) a pressure-sensitive adhesive surface adapted for contact with the skin or mucosa and positionedon one surface of the reservoir remote from the backing member and wherein one or more drug release rate controlling microporous membranes are interposed between the surface of the reservoir and pressure-sensitive adhesive so as to continuously meter the flow of a therapeutically effective amount of the drug from the reservoir at a controlled and predetermined rate over a period of time.
4. The bandage as defined by claim 3 wherein the reservoir is a container having the drug confined therein.
5. The bandage as defined by claim 4 wherein the reservoir is pressurized to permit controlled microporous flow of the drug from the reservoir.
6. The bandage as defined by claim 3 wherein the reservoir is a solid or microporous matrix having the drug dispersed therein.
7. The bandage as defined by claim 3 wherein the pores of the microporous rate controlling material are filled with a medium to permit controlled diffusion of the drug from the reservoir.
|Brevet cité||Date de dépôt||Date de publication||Déposant||Titre|
|US3053255 *||16 déc. 1958||11 sept. 1962||Meyer Friedrich||Process of percutaneously administering exact doses of physiologically active agents and composite unit therefor|
|US3426754 *||14 sept. 1966||11 févr. 1969||Celanese Corp||Breathable medical dressing|
|US3464413 *||26 mai 1967||2 sept. 1969||United Merchants & Mfg||Medical bandages|
|US3512997 *||29 sept. 1966||19 mai 1970||Tee Pak Inc||Extrusion of microporous collagen articles|
|US3598122 *||1 avr. 1969||23 nov. 1982||Titre non disponible|
|US3598123 *||1 avr. 1969||10 août 1971||Alza Corp||Bandage for administering drugs|
|Brevet citant||Date de dépôt||Date de publication||Déposant||Titre|
|US3972995 *||14 avr. 1975||3 août 1976||American Home Products Corporation||Dosage form|
|US4031894 *||7 sept. 1976||28 juin 1977||Alza Corporation||Bandage for transdermally administering scopolamine to prevent nausea|
|US4039653 *||21 juil. 1975||2 août 1977||Defoney, Brenman, Mayes & Baron||Long-acting articles for oral delivery and process|
|US4060084 *||28 janv. 1977||29 nov. 1977||Alza Corporation||Method and therapeutic system for providing chemotherapy transdermally|
|US4201211 *||12 juil. 1977||6 mai 1980||Alza Corporation||Therapeutic system for administering clonidine transdermally|
|US4230105 *||13 nov. 1978||28 oct. 1980||Merck & Co., Inc.||Transdermal delivery of drugs|
|US4262003 *||14 mars 1977||14 avr. 1981||Alza Corporation||Method and therapeutic system for administering scopolamine transdermally|
|US4286592 *||4 févr. 1980||1 sept. 1981||Alza Corporation||Therapeutic system for administering drugs to the skin|
|US4341208 *||14 juil. 1980||27 juil. 1982||Whitman Medical Corporation||Moisture-retentive covering for ointment application|
|US4432756 *||27 nov. 1981||21 févr. 1984||Alza Corporation||Parenteral controlled therapy|
|US4460372 *||1 avr. 1983||17 juil. 1984||Alza Corporation||Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer|
|US4479793 *||11 oct. 1983||30 oct. 1984||Alza Corporation||Parenteral administration using drug delivery device|
|US4479794 *||11 oct. 1983||30 oct. 1984||Alza Corporation||System for intravenous therapy|
|US4484909 *||17 oct. 1983||27 nov. 1984||Alza Corporation||Parenteral therapy using solid drug|
|US4493702 *||17 oct. 1983||15 janv. 1985||Alza Corporation||Parenteral administration using osmotically motivated delivery system|
|US4511351 *||14 mai 1984||16 avr. 1985||Alza Corporation||Parenteral delivery system utilizing a hollow fiber cellular unit|
|US4511352 *||14 mai 1984||16 avr. 1985||Alza Corporation||Parenteral delivery system with in-line container|
|US4511353 *||9 oct. 1981||16 avr. 1985||Alza Corporation||Intravenous system for delivering a beneficial agent|
|US4515585 *||31 oct. 1983||7 mai 1985||Alza Corporation||System for parenteral administration of agent|
|US4525162 *||9 mars 1984||25 juin 1985||Alza Corporation||Parenteral controlled delivery|
|US4548599 *||5 janv. 1984||22 oct. 1985||Alza Corporation||Parenteral controlled therapy|
|US4552556 *||4 janv. 1985||12 nov. 1985||Alza Corporation||Parenteral controlled therapy|
|US4573996 *||3 janv. 1984||4 mars 1986||Jonergin, Inc.||Device for the administration of an active agent to the skin or mucosa|
|US4579553 *||7 janv. 1985||1 avr. 1986||Alza Corporation||Parenteral controlled therapy|
|US4583981 *||7 janv. 1985||22 avr. 1986||Alza Corporation||Parenteral controlled therapy, using a porous matrix with parenteral agent|
|US4585452 *||12 avr. 1983||29 avr. 1986||Key Pharmaceuticals, Inc.||Transdermal systemic dosage forms|
|US4586922 *||15 févr. 1985||6 mai 1986||Alza Corporation||Intravenous system for delivering a beneficial agent|
|US4596555 *||28 janv. 1985||24 juin 1986||Alza Corporation||Parenteral delivery system utilizing a hollow fiber cellular unit|
|US4615697 *||9 nov. 1984||7 oct. 1986||Bio-Mimetics, Inc.||Bioadhesive compositions and methods of treatment therewith|
|US4624665 *||1 oct. 1984||25 nov. 1986||Biotek, Inc.||Method of transdermal drug delivery|
|US4645502 *||3 mai 1985||24 févr. 1987||Alza Corporation||Transdermal delivery of highly ionized fat insoluble drugs|
|US4655767 *||26 sept. 1985||7 avr. 1987||Dow Corning Corporation||Transdermal drug delivery devices with amine-resistant silicone adhesives|
|US4661105 *||9 juin 1986||28 avr. 1987||Alza Corporation||Medical bandage for administering vasodilator drug|
|US4664650 *||31 oct. 1983||12 mai 1987||Alza Corporation||Apparatus for parenteral infusion of fluid containing beneficial agent|
|US4666441 *||17 déc. 1985||19 mai 1987||Ciba-Geigy Corporation||Multicompartmentalized transdermal patches|
|US4671953 *||1 mai 1985||9 juin 1987||University Of Utah Research Foundation||Methods and compositions for noninvasive administration of sedatives, analgesics, and anesthetics|
|US4680172 *||5 mars 1985||14 juil. 1987||Ciba-Geigy Corporation||Devices and methods for treating memory impairment|
|US4690683 *||2 juil. 1985||1 sept. 1987||Rutgers, The State University Of New Jersey||Transdermal varapamil delivery device|
|US4698062 *||30 oct. 1985||6 oct. 1987||Alza Corporation||Medical device for pulsatile transdermal delivery of biologically active agents|
|US4704119 *||19 nov. 1986||3 nov. 1987||Alza Corporation||Method comprising transdermal and buccal treatment of angina|
|US4710191 *||16 déc. 1985||1 déc. 1987||Jonergin, Inc.||Therapeutic device for the administration of medicaments|
|US4725272 *||29 juin 1981||16 févr. 1988||Alza Corporation||Novel bandage for administering beneficial drug|
|US4738670 *||10 juil. 1987||19 avr. 1988||Bayer Aktiengesellschaft||Medicinal plasters|
|US4740103 *||15 févr. 1985||26 avr. 1988||Alza Corporation||Intravenous system for delivering a beneficial agent|
|US4740197 *||14 févr. 1985||26 avr. 1988||Alza Corporation||Intravenous system for delivering a beneficial agent via polymer delivery|
|US4740198 *||15 févr. 1985||26 avr. 1988||Alza Corporation||Method of administering intravenous drug using rate-controlled dosage form|
|US4740199 *||14 févr. 1985||26 avr. 1988||Alza Corporation||Intravenous system for delivering a beneficial agent|
|US4740200 *||15 févr. 1985||26 avr. 1988||Alza Corporation||Intravenous system for delivering a beneficial agent|
|US4740201 *||19 févr. 1985||26 avr. 1988||Alza Corporation||Intravenous system for delivering a beneficial agent|
|US4741734 *||15 févr. 1985||3 mai 1988||Alza Corporation||Releasing means for adding agent using releasing means to IV fluid|
|US4741735 *||14 févr. 1985||3 mai 1988||Alza Corporation||Intravenous system for delivering a beneficial agent|
|US4743249 *||10 juin 1987||10 mai 1988||Ciba-Geigy Corp.||Dermal and transdermal patches having a discontinuous pattern adhesive layer|
|US4752478 *||17 déc. 1984||21 juin 1988||Merck & Co., Inc.||Transdermal system for timolol|
|US4756710 *||7 mars 1986||12 juil. 1988||Merck & Co., Inc.||pH-Mediated drug delivery system|
|US4764379 *||24 août 1987||16 août 1988||Alza Corporation||Transdermal drug delivery device with dual permeation enhancers|
|US4765985 *||20 mai 1987||23 août 1988||Ciba-Geigy Corporation||Devices and methods for treating memory impairment|
|US4776850 *||12 mai 1986||11 oct. 1988||Beiersdorf Aktiengesellschaft||Nitrate-containing plaster|
|US4790820 *||25 oct. 1984||13 déc. 1988||Alza Corporation||Parenteral agent dispensing equipment with drug releasing member|
|US4795436 *||22 sept. 1986||3 janv. 1989||Bio-Mimetics, Inc.||Bioadhesive composition and method of treatment therewith|
|US4812305 *||9 nov. 1987||14 mars 1989||Vocal Rodolfo S||Well medicine strip|
|US4812313 *||14 déc. 1987||14 mars 1989||Alza Corporation||Method for lessening the incidence of anginal attacks|
|US4820720 *||29 mars 1988||11 avr. 1989||Alza Corporation||Transdermal drug composition with dual permeation enhancers|
|US4833172 *||15 sept. 1988||23 mai 1989||Ppg Industries, Inc.||Stretched microporous material|
|US4834979 *||14 déc. 1987||30 mai 1989||Alza Corporation||Medical bandage for administering beneficial drug|
|US4836217 *||23 sept. 1985||6 juin 1989||Fischer Torkel I||Hypersensitivity test means|
|US4839174 *||5 oct. 1987||13 juin 1989||Pharmetrix Corporation||Novel transdermal nicotine patch|
|US4846826 *||21 nov. 1986||11 juil. 1989||Alza Corporation||Method for treating ischemic conditions|
|US4849226 *||14 déc. 1987||18 juil. 1989||Alza Corporation||Method for increasing oxygen supply by administering vasodilator|
|US4857052 *||4 mai 1987||15 août 1989||Alza Corporation||Intravenous system for delivering a beneficial agent|
|US4861644 *||30 août 1988||29 août 1989||Ppg Industries, Inc.||Printed microporous material|
|US4863737 *||8 juin 1987||5 sept. 1989||University Of Utah||Compositions and methods of manufacture of compressed powder medicaments|
|US4863738 *||23 nov. 1987||5 sept. 1989||Alza Corporation||Skin permeation enhancer compositions using glycerol monooleate|
|US4871360 *||21 avr. 1986||3 oct. 1989||Alza Corporation||System for intravenous delivery of a beneficial drug at a regulated rates|
|US4877618 *||18 mars 1988||31 oct. 1989||Reed Jr Fred D||Transdermal drug delivery device|
|US4885173 *||8 juin 1987||5 déc. 1989||University Of Utah||Methods and compositions for noninvasive dose-to-effect administration of drugs with cardiovascular or renal vascular activities|
|US4898920 *||15 oct. 1987||6 févr. 1990||Dow Corning Corporation||Adhesive compositions, controlled release compositions and transdermal delivery device|
|US4904475 *||24 févr. 1987||27 févr. 1990||Alza Corporation||Transdermal delivery of drugs from an aqueous reservoir|
|US4906463 *||8 avr. 1988||6 mars 1990||Cygnus Research Corporation||Transdermal drug-delivery composition|
|US4906475 *||16 févr. 1988||6 mars 1990||Paco Pharmaceutical Services||Estradiol transdermal delivery system|
|US4908019 *||16 sept. 1988||13 mars 1990||Alza Corporation||Apparatus comprising dual reservoirs for parenteral infusion of fluid containing beneficial agent|
|US4911707 *||10 août 1988||27 mars 1990||Ciba-Geigy Corporation||Monolithic user-activated transdermal therapeutic system|
|US4917688 *||27 juin 1988||17 avr. 1990||Nelson Research & Development Co.||Bandage for transdermal delivery of systemically-active drug|
|US4938759 *||2 sept. 1986||3 juil. 1990||Alza Corporation||Transdermal delivery device having a rate controlling adhesive|
|US4943435 *||28 oct. 1988||24 juil. 1990||Pharmetrix Corporation||Prolonged activity nicotine patch|
|US4954344 *||10 nov. 1988||4 sept. 1990||Alza Corporation||Method for treating nocturnal angina|
|US4969871 *||15 févr. 1989||13 nov. 1990||Alza Corporation||Intravenous system for delivering a beneficial agent|
|US4971800 *||18 sept. 1989||20 nov. 1990||The Regents Of The University Of California||Method and compositions for enhancing the cutaneous penetration of pharmacologically active agents|
|US4973307 *||25 avr. 1989||27 nov. 1990||Alza Corporation||Method for administering drugs to a patient|
|US4973468 *||22 mars 1989||27 nov. 1990||Cygnus Research Corporation||Skin permeation enhancer compositions|
|US4983392 *||20 déc. 1988||8 janv. 1991||Bio-Mimetics, Inc.||Bioadhesive compositions and methods of treatment therewith|
|US4985017 *||25 avr. 1989||15 janv. 1991||Alza Corporation||Parenteral therapeutical system comprising drug cell|
|US4994031 *||17 avr. 1989||19 févr. 1991||Alza Corporation||Intravenous system for delivering a beneficial agent|
|US5006342 *||10 févr. 1989||9 avr. 1991||Cygnus Corporation||Resilient transdermal drug delivery device|
|US5024657 *||4 mai 1990||18 juin 1991||Baxter International Inc.||Drug delivery apparatus and method preventing local and systemic toxicity|
|US5028435 *||22 mai 1989||2 juil. 1991||Advanced Polymer Systems, Inc.||System and method for transdermal drug delivery|
|US5035894 *||8 sept. 1989||30 juil. 1991||Dow Corning Corporation||Controlled release compositions and transdermal drug delivery device|
|US5045059 *||15 août 1990||3 sept. 1991||Alza Corporation||Intravenous system for delivering a beneficial agent|
|US5045317 *||20 sept. 1990||3 sept. 1991||The Regents Of The University Of California||Enhancing the cutaneous penetration of pharmacologically active agents|
|US5051260 *||20 sept. 1990||24 sept. 1991||The Regents Of The University Of California||Method and composition for enhancing the cutaneous penetration of pharmacologically active agents|
|US5053227 *||12 juin 1990||1 oct. 1991||Cygnus Therapeutic Systems||Skin permeation enhancer compositions, and methods and transdermal systems associated therewith|
|US5059189 *||8 sept. 1987||22 oct. 1991||E. R. Squibb & Sons, Inc.||Method of preparing adhesive dressings containing a pharmaceutically active ingredient|
|US5059426 *||12 juin 1990||22 oct. 1991||Cygnus Therapeutic Systems||Skin permeation enhancer compositions, and methods and transdermal systems associated therewith|
|US5069671 *||23 juin 1988||3 déc. 1991||Alza Corporation||Intravenous medication|
|US5071656 *||14 nov. 1988||10 déc. 1991||Alza Corporation||Delayed onset transdermal delivery device|
|US5080646 *||3 oct. 1988||14 janv. 1992||Alza Corporation||Membrane for electrotransport transdermal drug delivery|
|US5091087 *||25 juin 1990||25 févr. 1992||Hoechst Celanese Corp.||Fabrication of microporous PBI membranes with narrow pore size distribution|
|US5091186 *||15 août 1989||25 févr. 1992||Cygnus Therapeutic Systems||Biphasic transdermal drug delivery device|
|US5122127 *||5 sept. 1989||16 juin 1992||University Of Utah||Apparatus and methods for use in administering medicaments by direct medicament contact to mucosal tissues|
|US5124157 *||18 août 1989||23 juin 1992||Cygnus Therapeutic Systems||Method and device for administering dexmedetomidine transdermally|
|US5132114 *||5 sept. 1989||21 juil. 1992||University Of Utah Research Foundation||Compositions and methods of manufacture of compressed powder medicaments|
|US5141750 *||14 nov. 1988||25 août 1992||Alza Corporation||Delayed onset transdermal delivery device|
|US5147296 *||28 août 1991||15 sept. 1992||Alza Corporation||Membrane for electrotransport transdermal drug delivery|
|US5151271 *||24 oct. 1989||29 sept. 1992||Nitti Electric Industrial Co., Ltd.||Pressure-sensitively adhering composite medicinal preparation|
|US5160320 *||14 févr. 1990||3 nov. 1992||Alza Corporation||Intravenous system for delivering a beneficial agent|
|US5164189 *||11 mars 1991||17 nov. 1992||G. D. Searle & Co.||Single layer transdermal drug administration system|
|US5164416 *||8 mai 1991||17 nov. 1992||Lintec Corporation||Transdermal therapeutic formulation containing a limonene|
|US5169382 *||30 janv. 1991||8 déc. 1992||Alza Corporation||Membrane for electrotransport transdermal drug delivery|
|US5169383 *||2 oct. 1989||8 déc. 1992||Alza Corporation||Control membrane for electrotransport drug delivery|
|US5213965 *||16 juil. 1990||25 mai 1993||Cholestech Corporation||Solid-phase precipitation assay device|
|US5232438 *||15 juin 1992||3 août 1993||Alza Corporation||Membrane for electrotransport transdermal drug delivery|
|US5234690 *||23 août 1991||10 août 1993||Cygnus Therapeutic Systems||Transdermal drug delivery device using an unfilled microporous membrane to achieve delayed onset|
|US5268179 *||14 févr. 1992||7 déc. 1993||Ciba-Geigy Corporation||Ultrasonically sealed transdermal drug delivery systems|
|US5273755 *||23 août 1991||28 déc. 1993||Cygnus Therapeutic Systems||Transdermal drug delivery device using a polymer-filled microporous membrane to achieve delayed onset|
|US5273756 *||23 août 1991||28 déc. 1993||Cygnus Therapeutic Systems||Transdermal drug delivery device using a membrane-protected microporous membrane to achieve delayed onset|
|US5288497 *||5 sept. 1989||22 févr. 1994||The University Of Utah||Compositions of oral dissolvable medicaments|
|US5290561 *||10 avr. 1992||1 mars 1994||G. D. Searle & Co.||Single layer transdermal drug administration system|
|US5298257 *||19 mars 1992||29 mars 1994||Elan Transdermal Limited||Method for the treatment of withdrawal symptoms associated with smoking cessation and preparations for use in said method|
|US5322502 *||13 janv. 1993||21 juin 1994||Alza Corporation||Membrane for electrotransport transdermal drug delivery|
|US5340585 *||17 mai 1993||23 août 1994||University Of Southern California||Method and formulations for use in treating benign gynecological disorders|
|US5340586 *||17 mai 1993||23 août 1994||University Of Southern California||Methods and formulations for use in treating oophorectomized women|
|US5378730 *||3 déc. 1992||3 janv. 1995||Alza Corporation||Permeation enhancer comprising ethanol and monoglycerides|
|US5405614 *||11 janv. 1993||11 avr. 1995||International Medical Associates, Inc.||Electronic transdermal drug delivery system|
|US5411740 *||8 févr. 1994||2 mai 1995||Alza Corporation||Transdermal administration of oxybutynin|
|US5422118 *||21 sept. 1992||6 juin 1995||Pure Pac, Inc.||Transdermal administration of amines with minimal irritation and high transdermal flux rate|
|US5451407 *||21 juin 1993||19 sept. 1995||Alza Corporation||Reduction or prevention of skin irritation or sensitization during transdermal administration of a irritating or sensitizing drug|
|US5484602 *||20 janv. 1995||16 janv. 1996||University Of Utah Research Foundation||Methods and compositions for noninvasive dose-to-effect administration of drugs with cardiovascular or renal vascular activities|
|US5498417 *||12 mai 1994||12 mars 1996||Coating Sciences, Inc.||Transdermal delivery of appetite suppressant drug|
|US5500222 *||15 févr. 1995||19 mars 1996||Alza Corporation||Transdermal administration of oxybutynin|
|US5505958 *||31 oct. 1994||9 avr. 1996||Algos Pharmaceutical Corporation||Transdermal drug delivery device and method for its manufacture|
|US5508039 *||16 oct. 1992||16 avr. 1996||Alza Corporation||Controlled transdermal administration of melatonin|
|US5512292 *||21 déc. 1994||30 avr. 1996||Alza Corporation||Transdermal contraceptive formulations methods and devices|
|US5582836 *||16 oct. 1991||10 déc. 1996||Vectorpharma International S.P.A.||Transdermal therapeutic compositions|
|US5591767 *||6 juin 1995||7 janv. 1997||Pharmetrix Corporation||Liquid reservoir transdermal patch for the administration of ketorolac|
|US5612382 *||15 juil. 1994||18 mars 1997||Frances B. Fike||Composition for percutaneous absorption of pharmaceutically active ingredients|
|US5633009 *||12 nov. 1993||27 mai 1997||Sano Corporation||Transdermal administration of azapirones|
|US5641507 *||26 oct. 1995||24 juin 1997||Devillez; Richard L.||Delivery system for dermatological and cosmetic ingredients|
|US5643596 *||7 juin 1995||1 juil. 1997||Clarion Pharmaceuticals, Inc.||Hemostatic patch|
|US5643905 *||10 janv. 1994||1 juil. 1997||Therapie-System Gmbh & Co., Kg||Pharmaceutical formulation for the treatment of nicotine dependence|
|US5645849 *||7 juin 1995||8 juil. 1997||Clarion Pharmaceuticals, Inc.||Hemostatic patch|
|US5650165 *||7 nov. 1995||22 juil. 1997||Nitto Denko Corporation||Percutaneous absorption preparation|
|US5668143 *||3 nov. 1994||16 sept. 1997||Merrell Pharmaceuticals Inc.||Heterocyclic benzenesulfonylimine derivatives as inhibitors of IL-1 action|
|US5684017 *||3 nov. 1994||4 nov. 1997||Merrell Pharmaceuticals Inc.||Benzenesulfonylimine derivatives as inhibitors of IL-1 action|
|US5707612 *||8 avr. 1996||13 janv. 1998||Alzo, Inc.||Use urethane polymers of castor oil skin and personal care product compositiions|
|US5728688 *||7 juin 1995||17 mars 1998||Endoreoherche, Inc.||Therapeutic methods and delivery systems utilizing sex steroid precursors|
|US5747065 *||29 sept. 1994||5 mai 1998||Lee; Eun Soo||Monoglyceride/lactate ester permeation enhancer for oxybutynin|
|US5750137 *||29 sept. 1994||12 mai 1998||Taskovich; Lina Tormen||Monoglyceride/lactate ester permeation enhancer|
|US5756117 *||10 août 1992||26 mai 1998||International Medical Asscociates, Inc.||Multidose transdermal drug delivery system|
|US5762952 *||27 avr. 1993||9 juin 1998||Hercon Laboratories Corporation||Transdermal delivery of active drugs|
|US5776923 *||18 janv. 1994||7 juil. 1998||Endorecherche, Inc.||Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone|
|US5780460 *||7 juin 1995||14 juil. 1998||Endoreoherche, Inc.||Therapeutic methods and delivery systems utilizing sex steroid precursors|
|US5785991 *||7 juin 1995||28 juil. 1998||Alza Corporation||Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate|
|US5798347 *||7 juin 1995||25 août 1998||Endorecherche, Inc.||Therapeutic methods and delivery systems utilizing sex steroid precursors|
|US5807571 *||7 oct. 1997||15 sept. 1998||Lts Lohmann Therapie-Systeme Gmbh||Transdermal therapeutic systems for administering indole serotonin agonists|
|US5807849 *||13 juin 1995||15 sept. 1998||Endorecherche, Inc.||Therapeutic methods and delivery systems utilizing sex steroid precursors|
|US5817331 *||7 juin 1995||6 oct. 1998||Sano Corporation||Transdermal administration of azapirones|
|US5820876 *||6 juin 1995||13 oct. 1998||Lts Lohmann Therapie-Systeme Gmbh & Co. Kg||Transdermal therapeutic system|
|US5824671 *||7 juin 1995||20 oct. 1998||Endorecherche Inc||Therapeutic methods and delivery systems utilizing sex steroid precursors|
|US5827529 *||10 juin 1994||27 oct. 1998||Teikoku Seiyaku Kabushiki Kaisha||External preparation for application to the skin containing lidocaine|
|US5837280 *||7 juin 1995||17 nov. 1998||Sano Corporation||Transdermal administration of azapirones|
|US5837700 *||7 juin 1995||17 nov. 1998||Endorecherche, Inc.||Therapeutic methods and delivery systems utilizing sex steroid precursors|
|US5840327 *||15 août 1996||24 nov. 1998||Alza Corporation||Transdermal drug delivery device having enhanced adhesion|
|US5843468 *||13 mai 1996||1 déc. 1998||Alza Corporation||Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate|
|US5843932 *||7 juin 1995||1 déc. 1998||Endorcaherche, Inc.||Therapeutic methods and delivery systems utilizing sex steroid precursors|
|US5854229 *||7 juin 1995||29 déc. 1998||Endorecherche, Inc.||Therapeutic methods and delivery systems utilizing sex steroid precursors|
|US5855908 *||15 nov. 1994||5 janv. 1999||University Of Utah Research Foundation||Non-dissolvable drug-containing dosage-forms for use in the transmucosal delivery of a drug to a patient|
|US5861170 *||22 mars 1994||19 janv. 1999||Lts Lohmann Therapie-Systeme Gmbh & Co. Kg||Acetylsalicyclic acid-containing transdermal application system for antithrombotic therapy|
|US5869086 *||25 avr. 1994||9 févr. 1999||Lts Lohmann Therapie-Systeme Gmbh||Systems for the controlled release of pilocarpine|
|US5872114 *||7 juin 1995||16 févr. 1999||Endorecherche, Inc.||Therapeutic methods and delivery systems utilizing sex steroid precursors|
|US5891868 *||21 nov. 1997||6 avr. 1999||Kaiser Foundation Health Plan, Inc.||Methods for treating postmenopausal women using ultra-low doses of estrogen|
|US5900250 *||30 avr. 1998||4 mai 1999||Alza Corporation||Monoglyceride/lactate ester permeation enhancer for oxybutnin|
|US5912009 *||29 oct. 1997||15 juin 1999||Theratech, Inc.||Fatty acid esters of glycolic acid and its salts|
|US5919478 *||24 juin 1994||6 juil. 1999||Alza Corporation||Incorporating poly-N-vinyl amide in a transdermal system|
|US5922700 *||7 juin 1995||13 juil. 1999||Endorecherche, Inc.||Therapeutic methods and delivery systems utilizing sex steroid precursors|
|US5932240 *||8 déc. 1997||3 août 1999||Americare Technology, Inc.||Multidose transdermal drug delivery system|
|US5939095 *||6 déc. 1994||17 août 1999||Lts Lohmann Therapie-Systeme Gmbh||Transdermal therapeutic system and a process for the combined transdermal application of physostigmine and scopolamine for the prophylaxis and pretreatment of a poisoning caused by highly toxic organophosphorus neurotoxins in particular soman|
|US5948434 *||7 juin 1995||7 sept. 1999||Endorecherche, Inc.||Therapeutic methods and delivery systems utilizing sex steroid precursors|
|US5952000 *||29 oct. 1997||14 sept. 1999||Theratech, Inc.||Fatty acid esters of lactic acid salts as permeation enhancers|
|US5955455 *||13 nov. 1997||21 sept. 1999||Endorecherche, Inc.||Therapeutic methods and delivery systems utilizing sex steroid precursors|
|US5962011 *||24 juin 1997||5 oct. 1999||Schering-Plough Healthcare Products, Inc.||Device for delivery of dermatological ingredients|
|US6001390 *||18 déc. 1996||14 déc. 1999||Alza Corporation||Formulations for transdermal delivery of pergolide|
|US6004578 *||23 oct. 1997||21 déc. 1999||Alza Corporation||Permeation enhances for transdermal drug delivery compositions, devices and methods|
|US6007837 *||3 févr. 1999||28 déc. 1999||Alza Corporation||Drug delivery devices and process of manufacture|
|US6074665 *||24 juin 1996||13 juin 2000||Lts Lohmann Therapie-Systeme Gmbh||Transdermal therapeutic system for administering active agents to the human body via the skin|
|US6110488 *||6 juin 1995||29 août 2000||Lts Lohmann Therapie-Systeme Gmbh & Co. Kg||Transdermal therapeutic system, its use and production process|
|US6117448 *||6 juin 1995||12 sept. 2000||Lts Lohmann Therapie-Systeme Gmbh & Co. Kg||Transdermal therapeutic system, its use and production process|
|US6126963 *||6 juin 1995||3 oct. 2000||Lts Lohmann Therapie-Systeme Gmbh & Co. Kg||Transdermal therapeutic system, its use and production process|
|US6139868 *||6 juin 1995||31 oct. 2000||Lts Lohmann Therapie-Systeme Gmbh & Co. Kg||Transdermal therapeutic system, its use and production process|
|US6143303 *||14 août 1999||7 nov. 2000||Janakiram; Chodavarapu||Analgesic anti-inflammatory composition and method of preparing from dodonaea sp|
|US6163720 *||3 déc. 1998||19 déc. 2000||Alza Corporation||Layered rate controlling membranes for use in an electrotransport device|
|US6174545||3 févr. 1999||16 janv. 2001||Alza Corporation||Drug delivery devices and process of manufacture|
|US6187322 *||5 janv. 1995||13 févr. 2001||Lts Lohmann Therapie-Systeme Gmbh||Process and a device for the production of a flat administration form comprising a preparation which contains pharmaceutical active substances|
|US6203817||5 juin 1998||20 mars 2001||Alza Corporation||Reduction of skin reactions caused by transdermal drug delivery|
|US6224900||9 mars 1998||1 mai 2001||Lts Lohmann Therapie-Systeme Gmbh & Co. Kg||Sealing bag for a transdermal therapeutic system|
|US6238700||5 mai 1998||29 mai 2001||Alza Corporation||Method for preventing crystal formation in a dispersion of a liquid in a matrix|
|US6264977||28 oct. 1999||24 juil. 2001||Lts Lohmann Therapie-Systeme Gmbh & Co. Kg||Transdermal therapeutic system, its use and production process|
|US6267984||17 déc. 1998||31 juil. 2001||Alza Corporation||Skin permeation enhancer compositions comprising a monoglyceride and ethyl palmitate|
|US6300327||6 févr. 1997||9 oct. 2001||The University Of Southern California||Compositions and methods for potentiation of neurotrophin activity|
|US6326524 *||2 mars 2000||4 déc. 2001||Bristol-Myers Squibb Company||Hydrocolloid foam dressing|
|US6348210||10 nov. 1999||19 févr. 2002||Alza Corporation||Methods for transdermal drug administration|
|US6375978||17 déc. 1998||23 avr. 2002||Alza Corporation||Rate controlling membranes for controlled drug delivery devices|
|US6465440||4 juin 2001||15 oct. 2002||Wellstat Therapeutics Corporation||Antimutagenic compositions for treatment and prevention of photodamage to skin|
|US6465445||11 juin 1998||15 oct. 2002||Endorecherche, Inc.||Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors|
|US6512010||14 juil. 1997||28 janv. 2003||Alza Corporation||Formulations for the administration of fluoxetine|
|US6537571||18 août 1998||25 mars 2003||Lts Lohmann Therapie-Systeme Ag||Transdermal therapeutic system containing the active substance scopolamine base|
|US6548510||8 févr. 2000||15 avr. 2003||Lts Lohmann Therapie Systeme Ag||Pharmaceutical composition containing deoxypeganine for the treatment of nicotine dependence|
|US6569448||17 oct. 1997||27 mai 2003||Alza Corporation||Method for preventing crystal formation in a dispersion of a liquid in a matrix|
|US6572879||7 juin 1995||3 juin 2003||Alza Corporation||Formulations for transdermal delivery of pergolide|
|US6592892||29 août 2000||15 juil. 2003||Tepha, Inc.||Flushable disposable polymeric products|
|US6627631 *||8 févr. 2000||30 sept. 2003||Lts Lohmann Therapie-Systeme Ag||Pharmaceutical composition containing desoxypeganine for the treatment of alcoholism|
|US6649681 *||5 févr. 2001||18 nov. 2003||Ferro Corporation||Adhesive composition primarily intended for use in medical applications|
|US6660295||29 sept. 1998||9 déc. 2003||Alza Corporation||Transdermal drug delivery device package with improved drug stability|
|US6670346||11 juin 1999||30 déc. 2003||Endorecherche, Inc.||Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors|
|US6692763||21 nov. 1998||17 févr. 2004||The Regents Of The University Of California||Methods for treating postmenopausal women using ultra-low doses of estrogen|
|US6698162 *||20 mars 2001||2 mars 2004||Teikoku Pharma Usa, Inc.||Methods of producing a terminally sterilized topical patch preparation|
|US6699497||23 juil. 1999||2 mars 2004||Alza Corporation||Formulations for the transdermal administration of fenoldopam|
|US6775570||18 avr. 2002||10 août 2004||Ceramatec, Inc.||Iontophoretic treatment device|
|US6933321||14 févr. 2003||23 août 2005||Endorecherche, Inc.||Antiandrogenic biphenyls|
|US6960353||29 sept. 2003||1 nov. 2005||Alza Corporation||Formulations for the transdermal administration of fenoldopam|
|US6974588||7 déc. 1999||13 déc. 2005||Elan Pharma International Limited||Transdermal patch for delivering volatile liquid drugs|
|US7011844||22 nov. 2002||14 mars 2006||Alza Corporation||Formulations for the administration of fluoxetine|
|US7047069||4 févr. 2002||16 mai 2006||Ceramatec, Inc.||Iontophoretic fluid delivery device|
|US7063859||18 sept. 2002||20 juin 2006||Noven Pharmaceuticals, Inc.||Barrier film lined backing layer composition and method for topical administration of active agents|
|US7087640||14 mars 2003||8 août 2006||Technology Commercialization Corp||Substance with sedative effect|
|US7166617||26 févr. 2001||23 janv. 2007||Mitsubishi Pharma Corporation||Cyclic amide derivatives|
|US7169409||8 sept. 2003||30 janv. 2007||Alza Corporation||Method for preventing crystal formation in a dispersion of a liquid in a matrix|
|US7349733||2 nov. 2001||25 mars 2008||Ceramatel, Inc.||Iontophoretic drug delivery systems|
|US7429576||30 déc. 2003||30 sept. 2008||Endorecherche, Inc.||Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors|
|US7553923||26 oct. 2007||30 juin 2009||Metabolix, Inc.||Medical devices and applications of polyhydroxyalkanoate polymers|
|US7622136||18 juin 2004||24 nov. 2009||Alza Corporation||Transparent transdermal nicotine delivery devices|
|US7641825||29 juil. 2005||5 janv. 2010||Tepha, Inc.||Method of making a polyhydroxyalkanoate filament|
|US7732430||23 mai 2002||8 juin 2010||Pantarhei Bioscience B.V.||Drug delivery system comprising a tetrahydroxilated estrogen for use in hormonal contraception|
|US7795038||8 avr. 2003||14 sept. 2010||Cholestech Corporation||High-density lipoprotein assay device and method|
|US7824879||9 janv. 2008||2 nov. 2010||Cholestech Corporation||Device and method for measuring LDL-associated cholesterol|
|US7871995||23 mai 2002||18 janv. 2011||Pantarhei Bioscience B.V.||Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception|
|US7884092||3 oct. 2006||8 févr. 2011||Endorecherche, Inc.||Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors|
|US7923440||11 juin 2003||12 avr. 2011||Pantarhei Bioscience B.V.||Method of treating or preventing immune mediated disorders and pharmaceutical formulation for use therein|
|US7943603||3 oct. 2006||17 mai 2011||Endorecherche, Inc.||Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors|
|US7943604||11 juin 2003||17 mai 2011||Pantarhei Bioscience B.V.||Method of treating human skin and a skin care composition for use in such a method|
|US7943683||31 oct. 2007||17 mai 2011||Tepha, Inc.||Medical devices containing oriented films of poly-4-hydroxybutyrate and copolymers|
|US7988991 *||7 mars 2002||2 août 2011||Hisamitsu Pharmaceutical Co., Inc.||Adhesive patch|
|US8017598||16 mai 2007||13 sept. 2011||Knopp Neurosciences, Inc.||Compositions of R(+) and S(−) pramipexole and methods of using the same|
|US8026228||23 mai 2002||27 sept. 2011||Pantarhei Bioscience B.V.||Estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy|
|US8034270||30 avr. 2004||11 oct. 2011||Tepha, Inc.||Polyhydroxyalkanoate medical textiles and fibers|
|US8048869 *||17 mai 2002||1 nov. 2011||Pantarhei Bioscience B.V.||Pharmaceutical composition for use in hormone replacement therapy|
|US8075911||20 août 2007||13 déc. 2011||Alza Corporation||Transparent transdermal nicotine delivery devices|
|US8084125||11 déc. 2009||27 déc. 2011||Tepha, Inc.||Non-curling polyhydroxyalkanoate sutures|
|US8124689||6 juin 2007||28 févr. 2012||Dow Corning Corporation||Silicone acrylate hybride composition and method of making same|
|US8188066||3 oct. 2006||29 mai 2012||Endorecherche, Inc.||Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors|
|US8197844||8 juin 2007||12 juin 2012||Activatek, Inc.||Active electrode for transdermal medicament administration|
|US8207159||18 avr. 2002||26 juin 2012||Hf Arzneimittelforschung Gmbh||Use of galanthamine for the treatment of pathological manifestations of the central nervous system based on intoxications with psychotropic substances|
|US8236785||7 janv. 2008||7 août 2012||Pantarhei Bioscience B.V.||Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method|
|US8241662||21 déc. 2006||14 août 2012||Watson Laboratories, Inc.||Unoccluded topical oxybutynin gel composition and methods for transdermal oxybutynin therapy|
|US8246979||22 juil. 2003||21 août 2012||Ucb Pharma Gmbh||Transdermal delivery system for the administration of rotigotine|
|US8246980 *||28 juil. 2003||21 août 2012||Ucb Pharma Gmbh||Transdermal delivery system|
|US8329734||27 juil. 2009||11 déc. 2012||Afgin Pharma Llc||Topical therapy for migraine|
|US8361272||27 juin 2007||29 janv. 2013||Ferring B.V.||Polyurethane elastomers|
|US8361273||6 sept. 2012||29 janv. 2013||Ferring B.V.||Polyurethane elastomers|
|US8389548||18 févr. 2005||5 mars 2013||Endorecherche, Inc.||Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors|
|US8440222 *||31 déc. 2009||14 mai 2013||Acino Ag||Reservoir system with closed membrane|
|US8445474||5 août 2011||21 mai 2013||Knopp Neurosciences, Inc.||Compositions of R(+) and S(−) pramipexole and methods of using the same|
|US8460707||26 mars 2012||11 juin 2013||Ferring B.V.||Stabilised prostaglandin composition|
|US8491934||28 juil. 2005||23 juil. 2013||Ferring B.V.||Stabilised prostaglandin composition|
|US8518926||14 déc. 2007||27 août 2013||Knopp Neurosciences, Inc.||Compositions and methods of using (R)-pramipexole|
|US8519148||14 mars 2008||27 août 2013||Knopp Neurosciences, Inc.||Synthesis of chirally purified substituted benzothiazole diamines|
|US8524254||15 oct. 2007||3 sept. 2013||Ferring B.V.||Bioresorbable polymers|
|US8524695||14 mars 2008||3 sept. 2013||Knopp Neurosciences, Inc.||Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same|
|US8557281||13 juil. 2010||15 oct. 2013||Ferring B.V.||Water-swellable polymers|
|US8569416||21 oct. 2011||29 oct. 2013||Dow Corning Corporation||Single phase silicone acrylate formulation|
|US8592424||29 juin 2009||26 nov. 2013||Afgin Pharma Llc||Topical regional neuro-affective therapy|
|US8614278||29 nov. 2011||24 déc. 2013||Dow Corning Corporation||Silicone acrylate hybrid composition and method of making same|
|US8617591||27 avr. 2012||31 déc. 2013||Ucb Pharma Gmbh||Transdermal delivery system for the administration of rotigotine|
|US8628798||10 août 2012||14 janv. 2014||Ferring B.V.||Water-swellable polymers|
|US8663680||5 déc. 2011||4 mars 2014||Alza Corporation||Transparent transdermal nicotine delivery devices|
|US8696637||28 févr. 2011||15 avr. 2014||Kimberly-Clark Worldwide||Transdermal patch containing microneedles|
|US8709482||31 mai 2013||29 avr. 2014||Ferring B.V.||Stabilised prostaglandin composition|
|US8715723||26 févr. 2007||6 mai 2014||Noven Pharmaceuticals, Inc.||Compositions and methods for delivery of amino-functional drugs|
|US8753555||11 avr. 2011||17 juin 2014||Tepha, Inc.||Medical devices containing oriented films of poly-4-hydroxybutyrate and copolymers|
|US8758657||16 juil. 2013||24 juin 2014||Tepha, Inc.||Process of making polyhydroxyalkanoate medical textiles|
|US8778382||30 avr. 2004||15 juil. 2014||Purdue Pharma L.P.||Tamper resistant transdermal dosage form|
|US8790689||18 nov. 2005||29 juil. 2014||Purdue Pharma L.P.||Tamper resistant transdermal dosage form|
|US8862223||18 janv. 2008||14 oct. 2014||Activatek, Inc.||Active transdermal medicament patch and circuit board for same|
|US8883830||13 janv. 2012||11 nov. 2014||Afgin Pharma LLC.||Topical therapy for the treatment of migraines, muscle sprains, muscle spasms, spasticity and related conditions|
|US8974813||27 juin 2007||10 mars 2015||Ferring B.V.||Hydrophilic polyurethane compositions|
|US8987240||23 oct. 2003||24 mars 2015||Pantarhei Bioscience B.V.||Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy|
|US8999379||27 févr. 2014||7 avr. 2015||Alza Corporation||Transparent transdermal nicotine delivery devices|
|US9012480||7 déc. 2012||21 avr. 2015||Afgin Pharma Llc||Topical therapy for migraine|
|US9034854||11 juil. 2003||19 mai 2015||Pantarhei Bioscience B.V.||Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy|
|US9040509||31 janv. 2011||26 mai 2015||Pantarhei Bioscience B.V.||Method of treating human skin and a skin care composition for use in such a method|
|US9090651||7 janv. 2005||28 juil. 2015||Endorecherche, Inc.||Helix 12 directed pharmaceutical products|
|US9125719||8 sept. 2011||8 sept. 2015||Tepha, Inc.||Polyhydroxyalkanoate medical textiles and fibers|
|US9205059||23 févr. 2015||8 déc. 2015||Alza Corporation||Transparent transdermal nicotine delivery devices|
|US9284345||9 avr. 2008||15 mars 2016||Endorecherche, Inc.||17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators|
|US9333066||13 mai 2014||10 mai 2016||Tepha, Inc.||Method of making a medical textile from polyhydroxyalkanoate fibers|
|US9468630||13 août 2013||18 oct. 2016||Knopp Biosciences Llc||Compositions and methods for treating conditions related to increased eosinophils|
|US9480770||28 févr. 2014||1 nov. 2016||Covidien Lp||Methods for preparation of medical dressing containing antimicrobial agent|
|US9512096||21 déc. 2012||6 déc. 2016||Knopp Biosciences, LLP||Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds|
|US9522262||27 avr. 2011||20 déc. 2016||Kimberly-Clark Worldwide, Inc.||Medical devices for delivery of siRNA|
|US9522263||27 avr. 2011||20 déc. 2016||Kimberly-Clark Worldwide, Inc.||Device for delivery of rheumatoid arthritis medication|
|US9526883||27 avr. 2011||27 déc. 2016||Kimberly-Clark Worldwide, Inc.||Composite microneedle array including nanostructures thereon|
|US9545507||27 avr. 2011||17 janv. 2017||Kimberly-Clark Worldwide, Inc.||Injection molded microneedle array and method for forming the microneedle array|
|US9555155||10 déc. 2015||31 janv. 2017||Tepha, Inc.||Methods of orienting multifilament yarn and monofilaments of poly-4-hydroxybutyrate and copolymers thereof|
|US9561238||12 févr. 2015||7 févr. 2017||Donesta Bioscience B.V.||Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy|
|US9586044||27 avr. 2011||7 mars 2017||Kimberly-Clark Worldwide, Inc.||Method for increasing the permeability of an epithelial barrier|
|US9642840||13 août 2014||9 mai 2017||Knopp Biosciences, Llc||Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders|
|US9662313||28 févr. 2014||30 mai 2017||Knopp Biosciences Llc||Compositions and methods for treating amyotrophic lateral sclerosis in responders|
|US9681936 *||30 nov. 2012||20 juin 2017||Covidien Lp||Multi-layer porous film material|
|US9682068||19 mai 2014||20 juin 2017||Mylan Inc.||Transdermal therapeutic system for extended dosing of pramipexole in treating neurological disorders|
|US9682960||11 déc. 2014||20 juin 2017||Endorecherche, Inc.||Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety|
|US9763918||13 août 2014||19 sept. 2017||Knopp Biosciences Llc||Compositions and methods for treating chronic urticaria|
|US9808554||21 juil. 2014||7 nov. 2017||Covidien Lp||Super soft foams|
|US20030088204 *||2 nov. 2001||8 mai 2003||Joshi Ashok V||Novel iontophoretic drug delivery systems|
|US20030118653 *||10 juin 2002||26 juin 2003||Lavipharm Laboratories Inc.||Quick dissolving oral mucosal drug delivery device with moisture barrier coating|
|US20030181516 *||14 mars 2003||25 sept. 2003||Krylov Boris Vladimirovich||Substance with sedative effect|
|US20030212094 *||26 févr. 2001||13 nov. 2003||Haruko Yamabe||Novel cyclic amide derivatives|
|US20030224471 *||8 avr. 2003||4 déc. 2003||Jones Ronald M.||High-Density lipoprotein assay device and method|
|US20040006134 *||14 févr. 2003||8 janv. 2004||Endorecherche, Inc.||Antiandrogenic biphenyls|
|US20040081683 *||28 juil. 2003||29 avr. 2004||Schacht Dietrich Wilhelm||Transdermal delivery system|
|US20040096491 *||7 mars 2002||20 mai 2004||Tetsuro Tateishi||Adhesive patch|
|US20040116406 *||18 avr. 2002||17 juin 2004||Klaus Opitz||Utilization of galanthamine for the treatment of pathologies of the central nervous system owing to intoxications with psychotropic substances|
|US20040132751 *||18 avr. 2002||8 juil. 2004||Klaus Opitz||Use of desoxypeganine for treating central nervous system symptoms resulting from intoxications by psychotrops|
|US20040142022 *||10 déc. 2003||22 juil. 2004||Jutaro Shudo||Methods of producing a terminally sterilized topical patch preparation|
|US20040157812 *||30 déc. 2003||12 août 2004||Endorecherche, Inc.||Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors|
|US20040167145 *||5 juil. 2002||26 août 2004||Klaus Opitz||Active ingredient combination for the pharmacological therapy of nicotine dependence|
|US20040186086 *||17 mai 2002||23 sept. 2004||Bunschoten Evert Johannes||Use of estrogen compounds to increase libido in women|
|US20040192620 *||23 mai 2002||30 sept. 2004||Bunschoten Evert Johannes||Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception|
|US20040192683 *||15 juin 2002||30 sept. 2004||Joachim Moormann||Active ingredient combination for treating a dependence on addictive substances or narcotics using medicaments|
|US20040198671 *||17 mai 2002||7 oct. 2004||Bunschoten Evert Johannes||Pharmaceutical composition for use in hormone replacement therapy|
|US20040198706 *||10 mars 2004||7 oct. 2004||Carrara Dario Norberto R.||Methods and formulations for transdermal or transmucosal application of active agents|
|US20040198710 *||23 mai 2002||7 oct. 2004||Bunschoten Evert Johannes||Drug delivery system comprising a tetrahydroxilated estrogen for use in hormonal contraception|
|US20040209909 *||9 avr. 2002||21 oct. 2004||Su Il Yum||Novel formulations for transdermal delivery of pergolide|
|US20040234576 *||30 avr. 2004||25 nov. 2004||Tepha, Inc., State Of Incorporation Delaware||Polyhydroxyalkanoate medical textiles and fibers|
|US20040234585 *||18 juin 2004||25 nov. 2004||Gale Robert M.||Transparent transdermal nicotine delivery devices|
|US20040258742 *||20 juil. 2004||23 déc. 2004||Van Osdol William Woodson||Transdermal administration of N-(2,5-disubstituted phenyl)-N'-(3-substituted phenyl)-N'-methyl guanidines|
|US20050002997 *||30 avr. 2004||6 janv. 2005||Howard Stephen A.||Tamper resistant transdermal dosage form|
|US20050025809 *||8 juil. 2004||3 févr. 2005||Tepha, Inc.||Poly-4-hydroxybutyrate matrices for sustained drug delivery|
|US20050048104 *||30 juin 2003||3 mars 2005||Venkatraman Subramanian S.||Transdermal drug delivery devices comprising a polyurethane drug reservoir|
|US20050053647 *||16 sept. 2004||10 mars 2005||Rudolf Matusch||Pharmaceutical product comprising the active substance diamorphine, and its use in a process for treating opiate addiction|
|US20050059645 *||2 août 2004||17 mars 2005||Bodor Nicholas S.||Methods for the treatment of male and female sexual dysfunction|
|US20050065062 *||24 sept. 2003||24 mars 2005||3M Innovative Properties Company||Method of formulating a pharmaceutical composition|
|US20050070488 *||23 mai 2002||31 mars 2005||Coelingh Bennik Herman Jan Tijmen||Estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy|
|US20050079206 *||22 juil. 2003||14 avr. 2005||Schacht Dietrich Wilhelm||Transdermal delivery system for the administration of rotigotine|
|US20050142475 *||30 déc. 2003||30 juin 2005||Moudry Ronald J.||Dry toner comprising encapsulated pigment, methods and uses|
|US20050186277 *||15 mars 2005||25 août 2005||Gale Robert M.||Novel formulations for the administration of fluoxetine|
|US20050215538 *||11 juin 2003||29 sept. 2005||Coelingh Bennink Herman J T||Method of treating human skin and a skin care composition for use in such a method|
|US20050250749 *||7 janv. 2005||10 nov. 2005||Endorecherche, Inc.||Helix 12 directed pharmaceutical products|
|US20050250750 *||3 sept. 2003||10 nov. 2005||The Regents Of The University Of California||Methods for treating postmenopausal women using ultra-low doses of estrogen|
|US20050261209 *||11 juin 2003||24 nov. 2005||Bunschoten Evert J||Method of treating or preventing immune mediated disorders and pharmaceutical formulation for use therein|
|US20050276807 *||15 juin 2004||15 déc. 2005||Advanced Biotherapy, Inc.||Treatment of acne|
|US20060008432 *||7 juil. 2004||12 janv. 2006||Sebastiano Scarampi||Gilsonite derived pharmaceutical delivery compositions and methods: nail applications|
|US20060058470 *||29 juil. 2005||16 mars 2006||Tepha, Inc.||Non-curling polyhydroxyalkanoate sutures|
|US20060063723 *||11 juil. 2003||23 mars 2006||Coelingh Bennink Herman Jan T||Pharmaceutical composition comprising esterol derivatives for use in cancer therapy|
|US20060177445 *||11 août 2005||10 août 2006||Boris Skurkovich||Treatment of inflammatory skin diseases|
|US20060177513 *||27 janv. 2006||10 août 2006||Tepha, Inc.||Embolization using poly-4-hydroxybutyrate particles|
|US20060199866 *||16 avr. 2004||7 sept. 2006||Joachim Moormann||Combination of desoxypeganine and mecamylanine for the treatment of alcohol abuse|
|US20060210613 *||14 mars 2006||21 sept. 2006||Carliss Richard D||Therapeutic wound care product|
|US20060247221 *||23 oct. 2003||2 nov. 2006||Coelingh Bennink Herman J T||Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy|
|US20060269475 *||11 avr. 2006||30 nov. 2006||Ryu Wonhyoung||Multi-layer structure having a predetermined layer pattern including an agent|
|US20060287659 *||20 août 2004||21 déc. 2006||Tepha, Inc.||Polyhydroxyalkanoate nerve regeneration devices|
|US20070027122 *||3 oct. 2006||1 févr. 2007||Endorecherche, Inc.||Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors|
|US20070027123 *||3 oct. 2006||1 févr. 2007||Endorecherche, Inc.||Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors|
|US20070065463 *||21 juin 2004||22 mars 2007||Ronald Aung-Din||Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions|
|US20070148195 *||21 déc. 2006||28 juin 2007||Ebert Charles D||Compositions and methods for transdermal oxybutynin therapy|
|US20070179210 *||31 janv. 2007||2 août 2007||Tyco Healthcare Group Lp||Super soft foams|
|US20070212314 *||27 juil. 2005||13 sept. 2007||Dow Corning Corporation||Silicone Adhesive Formulation Containing An Antiperspirant|
|US20070212410 *||26 févr. 2007||13 sept. 2007||Noven Pharmaceuticals, Inc.||Compositions and methods for delivery of amino-functional drugs|
|US20070237812 *||9 mars 2007||11 oct. 2007||Tyco Healthcare Group||Multi-layer wound dressings|
|US20070259930 *||10 avr. 2007||8 nov. 2007||Knopp Neurosciences, Inc.||Compositions and methods of using r(+) pramipexole|
|US20080014259 *||16 mai 2007||17 janv. 2008||Knopp Neurosciences, Inc.||Compositions of R(+) and S(-) Pramipexole and Methods of Using the Same|
|US20080031933 *||20 août 2007||7 févr. 2008||Alza Corporation||Transparent transdermal nicotine delivery devices|
|US20080051490 *||9 août 2007||28 févr. 2008||Williams Simon F||Medical Devices and Applications of Polyhydroxyalkanoate Polymers|
|US20080090894 *||3 déc. 2007||17 avr. 2008||Ronald Aung-Din||Transdermal migraine therapy|
|US20080095823 *||26 oct. 2007||24 avr. 2008||Metabolix, Inc.||Medical Devices and Applications of Polyhydroxyalkanoate Polymers|
|US20080119449 *||3 déc. 2007||22 mai 2008||The Regents Of The University Of California||Methods for treating postmenopausal women using ultra-low doses of estrogen|
|US20080132602 *||31 oct. 2007||5 juin 2008||Tepha, Inc.||Medical devices containing oriented films of poly-4-hydroxybutyrate and copolymers|
|US20080160065 *||12 juil. 2007||3 juil. 2008||Janet Anne Halliday||Drug delivery polymer with hydrochloride salt of clindamycin|
|US20080166745 *||9 janv. 2008||10 juil. 2008||Cholestech Corporation||Device and method for measuring LDL-associated cholesterol|
|US20080177219 *||23 janv. 2007||24 juil. 2008||Joshi Ashok V||Method for Iontophoretic Fluid Delivery|
|US20080188791 *||2 févr. 2007||7 août 2008||Difiore Attilio E||Active iontophoresis delivery system|
|US20080227985 *||14 mars 2008||18 sept. 2008||Knopp Neurosciences, Inc.||Synthesis of chirally purified substituted benzothiazoles|
|US20080305154 *||8 juin 2007||11 déc. 2008||Activatek, Inc.||Transdermal medicament patch and active electrode for same|
|US20090042844 *||9 avr. 2008||12 févr. 2009||Endorecherche, Inc.||17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators|
|US20090042956 *||14 déc. 2007||12 févr. 2009||Knopp Neurosciences, Inc.||Compositions and methods of using (r)-pramipexole|
|US20090047334 *||12 août 2008||19 févr. 2009||Patricia Williams||Transdermal patch for extended delivery of calcium|
|US20090054504 *||14 mars 2008||26 févr. 2009||Knopp Neurosciences, Inc.||Modified Release Formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and Methods of Using the Same|
|US20090098069 *||12 sept. 2008||16 avr. 2009||Drugtech Corporation||Transdermal, alcohol-free, pharmaceutical compositions|
|US20090169602 *||23 nov. 2006||2 juil. 2009||Universität Zürich||Allergy Treatment by Epicutaneous Allergen Administration|
|US20090196911 *||6 juin 2007||6 août 2009||Loubert Gary L||Silicone Acrylate Hybride Composition and Method Of Making Same|
|US20090209983 *||10 sept. 2008||20 août 2009||Tepha, Inc.||Polyhydroxyalkanoate nerve regeneration devices|
|US20090291120 *||27 juin 2007||26 nov. 2009||Jukka Tuominen||Hydrophilic Polyurethane Compositions|
|US20090324692 *||27 juin 2007||31 déc. 2009||Controlled Therapeutics (Scotland) Limited||Polyurethane Elastomers|
|US20100055437 *||27 août 2009||4 mars 2010||Tyco Healthcare Group Lp||Anti-microbial fibers and related articles and methods|
|US20100093237 *||11 déc. 2009||15 avr. 2010||Tepha, Inc.||Non-curling polyhydroxyalkanoate sutures|
|US20100113346 *||7 janv. 2008||6 mai 2010||Pantarhei Bioscience B.V.||Method of Treating or Preventing Infertility in a Female Mammal and Pharmaceutical Kit for Use in Such Method|
|US20100172959 *||31 déc. 2009||8 juil. 2010||Acino Ag||Reservoir system with closed membrane|
|US20100317745 *||15 oct. 2007||16 déc. 2010||Donald Magnus Nicolson||Bioresorbable Polymers|
|US20110009460 *||21 juin 2010||13 janv. 2011||Valentin Gribkoff||Compositions and methods for treating amyotrophic lateral sclerosis|
|US20110021596 *||27 juil. 2009||27 janv. 2011||Ronald Aung-Din||Topical therapy for migraine|
|US20110033515 *||4 août 2009||10 févr. 2011||Rst Implanted Cell Technology||Tissue contacting material|
|US20110091488 *||13 juil. 2010||21 avr. 2011||Controlled Therapeutics (Scotland) Limited||Water-swellable polymers|
|US20110160173 *||31 janv. 2011||30 juin 2011||Pantarhei Bioscience B.V.||Method Of Treating Human Skin And A Skin Care Composition For Use In Such A Method|
|US20110189475 *||11 avr. 2011||4 août 2011||Tepha, Inc.||Medical devices containing oriented films of poly-4-hydroxybutyrate and copolymers|
|US20110190356 *||19 août 2009||4 août 2011||Knopp Neurosciences Inc.||Compositions and Methods of Using (R)- Pramipexole|
|US20120245538 *||2 déc. 2010||27 sept. 2012||Michael Horstmann||Transdermal Therapeutic System for the Administration of Peptides|
|US20140034058 *||29 mars 2012||6 févr. 2014||Resmed R&D Germany Gmbh||Cushion for patient interface|
|US20140155916 *||30 nov. 2012||5 juin 2014||Covidien Lp||Multi-Layer Porous Film Material|
|USRE34365 *||5 août 1991||31 août 1993||Intravenous system for delivering a beneficial agent|
|USRE35474 *||13 oct. 1994||11 mars 1997||Dow Corning Corporation||Transdermal drug delivery devices with amine-resistant silicone adhesives|
|USRE37934||3 févr. 2000||10 déc. 2002||Lts Lohmann Therapie-Systeme Ag||Transdermal therapeutic system|
|CN101010065B||27 juil. 2005||29 févr. 2012||陶氏康宁公司||Silicone adhesive formulation containing an antiperspirant|
|DE2604718A1 *||6 févr. 1976||19 août 1976||Alza Corp||Therapeutische vorrichtung zur verabreichung von skopolaminbase|
|DE2647581A1 *||21 oct. 1976||27 avr. 1978||Henkel Kgaa||Blisterpackung|
|DE3205258A1 *||15 févr. 1982||16 sept. 1982||Alza Corp||Dosierungseinheit zur gleichzeitigen verabreichung von wirkstoffen und die perkutane absorption verstaerkenden mitteln|
|DE4241128A1 *||7 déc. 1992||24 juin 1993||Lohmann Therapie Syst Lts||Transdermal aspirin dosage forms - for antithrombotic therapy or cancer prophylaxis|
|DE102010053792A1||8 déc. 2010||14 juin 2012||Frank Becher||Device for germ-free keeping of surfaces, such as door handles, handrails, grip bars, handles of shopping carts and toilet seating surfaces, has flat support material and self-adhesive portion formed on one side of flat support material|
|EP0114125A2 *||18 janv. 1984||25 juil. 1984||Almedco, Inc.||Medication application systems|
|EP0114125A3 *||18 janv. 1984||22 mai 1985||Almedco, Inc.||Medication application systems|
|EP0153200A2 *||21 févr. 1985||28 août 1985||Yamanouchi Pharmaceutical Co., Ltd.||Medicinal patch|
|EP0153200A3 *||21 févr. 1985||25 sept. 1985||Yamanouchi Pharmaceutical Co., Ltd.||Medicinal patch|
|EP0174108A2 *||9 août 1985||12 mars 1986||Leonora I. Jost||Transdermal delivery devices|
|EP0174108A3 *||9 août 1985||25 mars 1987||Leonora Jost||Transdermal delivery devices and method of producing them|
|EP0196769A2 *||24 févr. 1986||8 oct. 1986||Rutgers, The State University of New Jersey||A novel transdermal pharmaceutical absorption dosage unit|
|EP0196769B1 *||24 févr. 1986||8 juil. 1992||Rutgers, The State University of New Jersey||A novel transdermal pharmaceutical absorption dosage unit|
|EP0261402A1 *||20 août 1987||30 mars 1988||LTS Lohmann Therapie-Systeme GmbH & Co. KG||Transcutaneous therapeutic device; use and preparation thereof|
|EP0272918A2 *||22 déc. 1987||29 juin 1988||Cygnus Therapeutic Systems||Diffusion matrix for transdermal drug administration and transdermal drug delivery devices including same|
|EP0272918A3 *||22 déc. 1987||24 août 1988||Cygnus Research Corporation||Diffusion matrix for transdermal drug administration and transdermal drug delivery devices including same|
|EP0273004A2 *||16 nov. 1987||29 juin 1988||Ciba-Geigy Ag||User-activated therapeutical system|
|EP0273004A3 *||16 nov. 1987||13 juil. 1988||Ciba-Geigy Ag||User-activated therapeutical system|
|EP0285563A1||24 mars 1988||5 oct. 1988||Ciba-Geigy Ag||Transdermal therapeutic systems for combinations of active agents|
|EP0316168A1 *||10 nov. 1988||17 mai 1989||Theratech, Inc.||Device for administering an active agent to the skin or mucosa|
|EP0439430A2 *||17 janv. 1991||31 juil. 1991||Ciba-Geigy Ag||Transdermal administration of zwitterionic drugs|
|EP0439430A3 *||17 janv. 1991||25 sept. 1991||Ciba-Geigy Ag||Transdermal administration of zwitterionic drugs|
|EP0481443A1 *||15 oct. 1991||22 avr. 1992||Vectorpharma International S.P.A.||Transdermal therapeutic compositions|
|EP0593807A1 *||22 oct. 1992||27 avr. 1994||LTS Lohmann Therapie-Systeme GmbH & Co. KG||Patch for transdermal administration of volatile pharmaceutically active ingredients of chemically basic nature and a process for preparation|
|EP0648264A1 *||2 juin 1993||19 avr. 1995||Case Western Reserve University||Bandage for continuous application of biologicals|
|EP0648264A4 *||2 juin 1993||1 oct. 1997||Univ Case Western Reserve||Bandage for continuous application of biologicals.|
|EP0841056A2 *||21 févr. 1996||13 mai 1998||Hisashi Mineta||Personal clothing with effects caused by weak electromagnetic waves|
|EP0841056A3 *||21 févr. 1996||24 nov. 1999||Hisashi Mineta||Personal clothing with effects caused by weak electromagnetic waves|
|EP1674068A1||19 févr. 1997||28 juin 2006||Acrux DDS Pty Ltd||Dermal penetration enhancers and drug delivery systems involving same|
|EP2087892A2||22 juin 2000||12 août 2009||Pharmacia & Upjohn Company LLC||(S,S) reboxetine for treating age associated learning and mental disorders|
|EP2090312A1||22 juin 2000||19 août 2009||Pharmacia & Upjohn Company LLC||(S,S) reboxetine for treating attention deficit disorder|
|EP2158903A2||14 déc. 1999||3 mars 2010||ALZA Corporation||Transparent Transdermal Nicotine Delivery Devices|
|EP2584016A1||19 oct. 2012||24 avr. 2013||Dow Corning Corporation||Single phase silicone acrylate formulation|
|EP2599847A1||29 nov. 2012||5 juin 2013||Dow Corning Corporation||A Silicone Acrylate Hybrid Composition and Method of Making Same|
|WO1980001139A1 *||6 déc. 1979||12 juin 1980||Svedman Paul||Device for treating tissues,for example skin|
|WO1982000005A1 *||26 juin 1981||7 janv. 1982||Key Pharma||Polymeric diffusion matrix containing a vasodilator|
|WO1987000042A1 *||27 juin 1986||15 janv. 1987||Rutgers, The State University Of New Jersey||Transdermal verapamil delivery device|
|WO1987001938A1 *||11 sept. 1986||9 avr. 1987||The Regents Of The University Of California||Liposome transdermal drug delivery system|
|WO1987003477A1 *||12 déc. 1985||18 juin 1987||Flexcon Company, Inc.||Transdermal methods and adhesives|
|WO1988001516A1 *||20 août 1987||10 mars 1988||Lohmann Gmbh & Co. Kg.||Transdermal therapeutic system, its use and production process|
|WO1992001498A2 *||15 juil. 1991||6 févr. 1992||Cholestech Corporation||Solid-phase precipitation assay device and method|
|WO1992001498A3 *||15 juil. 1991||5 mars 1992||Cholestech Corp||Solid-phase precipitation assay device and method|
|WO1993003692A1 *||14 août 1992||4 mars 1993||Cygnus Therapeutic Systems||Transdermal drug delivery device using a membrane-protected microporous membrane to achieve delayed onset|
|WO1993003693A1 *||17 août 1992||4 mars 1993||Cygnus Therapeutic Systems||Transdermal drug delivery device using a polymer-filled microporous membrane to achieve delayed onset|
|WO1994008571A2 *||20 oct. 1993||28 avr. 1994||Lts Lohmann Therapie-Systeme Gmbh & Co. Kg||Plaster for the transdermal administration of volatile, pharmaceutically active, chemically alkaline ingredients, and processs for producing the same|
|WO1994008571A3 *||20 oct. 1993||26 mai 1994||Lts Lohmann Therapie-Systeme Gmbh & Co. Kg||Plaster for the transdermal administration of volatile, pharmaceutically active, chemically alkaline ingredients, and processs for producing the same|
|WO1997004818A2 *||24 juin 1996||13 févr. 1997||Lts Lohmann Therapie-Systeme Gmbh||Transdermal therapeutic sysgtem for administering active agents to the human body via the skin|
|WO1997004818A3 *||24 juin 1996||13 mars 1997||Lohmann Therapie Syst Lts||Transdermal therapeutic sysgtem for administering active agents to the human body via the skin|
|WO1999011265A1 *||18 août 1998||11 mars 1999||Lts Lohmann Therapie-Systeme Ag||Transdermal therapeutic system containing the active substance scopolamine base|
|WO2000030693A1 *||23 sept. 1999||2 juin 2000||Deotexis Inc.||Dressing|
|WO2002062292A2 *||23 janv. 2002||15 août 2002||Ferro Corporation||Adhesive composition primarily intended for use in medical applications|
|WO2002062292A3 *||23 janv. 2002||31 oct. 2002||Ferro Corp||Adhesive composition primarily intended for use in medical applications|
|WO2005066194A1||6 janv. 2005||21 juil. 2005||Endorecherche, Inc.||Helix 12 directed steroidal pharmaceutical products|
|WO2008104032A1 *||29 févr. 2008||4 sept. 2008||D-Swell Pty Ltd||Body wrap with sodium carbonate dosage pack|
|WO2008124922A1||11 avr. 2008||23 oct. 2008||Endorecherche, Inc.||17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators|
|WO2011135530A2||27 avr. 2011||3 nov. 2011||Kimberly-Clark Worldwide, Inc.||Device for delivery of rheumatoid arthritis medication|
|WO2011135531A2||27 avr. 2011||3 nov. 2011||Kimberly-Clark Worldwide, Inc.||MEDICAL DEVICES FOR DELIVERY OF siRNA|
|WO2011135532A2||27 avr. 2011||3 nov. 2011||Kimberly-Clark Worldwide, Inc.||Composite microneedle array including nanostructures thereon|
|WO2017095730A1 *||28 nov. 2016||8 juin 2017||Elliptical Therapeutics, Llc||Systems and methods for transdermal drug delivery|
|Classification aux États-Unis||424/434, 424/448, 424/449|
|Classification internationale||A61K9/00, A61L15/58, A61F9/00, A61M31/00, A61L15/16, A61K9/70|
|Classification coopérative||A61K9/7076, A61M31/002, A61K9/7061, A61K9/7092, A61K9/7084, A61K9/0004, A61L15/58, A61F9/0017|
|Classification européenne||A61M31/00D, A61F9/00B2, A61K9/00L4, A61L15/58, A61K9/70E2B6B2, A61K9/70E2D, A61K9/70E2B8, A61K9/70E2K|